Patent Application
20220402909
The present invention relates to a novel compound having an inhibitory activity against glucosylceramide synthase (GCS), i.e., derivatives having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof.
Lysosomal storage disorders (LSDs) are the metabolic disorders that result from genetic lack or deficiency of certain enzymes in lysosomes. LSDs exhibit various pathological symptoms throughout the body, as the non-metabolized or non-degraded substrates are accumulated. Currently, about 50 types of LSDs are known and are largely classified into the diseases such as mucopolysaccaridose, oligosaccharidosis, and sphingolipidoses, depending on the substances accumulated.
Among the diseases, sphingolipidoses, which are a class of glycolipid storage disorders relating to sphingolipid metabolism, show pathologies due to the accumulation of various membrane glycosphingolipids (GSLs), such as glucosylceramide, trihexocylceramide, etc. For example, when the enzymes related to sphingolipid metabolism, such as beta-glucosidase, alpha-galactosidase, etc., do not have normal activity, the substrates thereof (e.g., glucosylceramide, trihexocylceramide, etc.) are accumulated, thereby exhibiting various pathologies, such as Gaucher disease, Fabry disease, etc.
There are known two types of therapies for the LSDs. The first method is to replace or supplement the insufficient or deficient metabolic enzymes. Although such an enzyme replacement therapy (ERT) is safe and effective, periodic intravenous administrations of the related enzyme(s) are required; the dose thereof should be adjusted according to the enzyme reaction(s); and the costs thereof are relatively high. Especially, since it is difficult to distribute the enzyme(s) toward the nervous system, the ERT does not show satisfactory efficacy in the treatment of symptoms related to the nervous system. In addition, there is also the problem that autoantibodies against the administered enzyme(s) are frequently generated.
The second method is a substrate reduction therapy (SRT) for inhibiting the syntheses of accumulated substrates. Glucosylceramide synthase (GCS) (also referred to as “UDP-glucose: ceramide glycosyltransferase”, “UDP-glucose: N-acylsphingosine D-glucosyltransferase”, or “EC 2.4.1.80”), which is an enzyme involved in sphingolipid metabolism, is involved in the reaction of ceramide with glucose to produce glucosylceramide. The resulting glucosylceramide is converted into various GSLs. Glucosylceramide synthase (GCS) inhibitors inhibit the activity of GCS, thereby reducing the production of glucosylceramide in the body and preventing abnormal accumulation of glycolipids, such as trihexocylceramide, GM1, and GM2, in cells or organs.
As such, GCS inhibitors inhibit the activity of GCS to prevent the accumulation of glycolipids and thus may be usefully applied to the treatment of lysosomal storage disorders, especially glycolipid storage disorders, such as GM1 gangliosidosis, Tay-Sachs disease, Sandhoff disease, Gaucher disease, Fabry disease, Niemann-Pick disease (types A and B), metachromatic leukodystrophy, Krabbe disease, etc. GCS inhibitors may be also used in the treatment of the secondary diseases associated with glycolipid storage, such as Niemann-Pick disease (type C), mucopolysaccharidosis, and mucolipidosis type IV (see, Chen C S, et al., Abnormal transport along the lysosomal pathway in mucolipidosis, type IV disease Proc Natl Acad Sci USA. 1998 May 26; 95(11):6373-8; and Goodman L A, et al., Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in alpha-mannosidosis, Proc Natl Acad Sci USA. 1991 Dec. 15; 88(24):11330-4). In addition, it has been reported to be useful in the treatment of diseases associated with the accumulation of glycolipids, such as renal hypertrophy (e.g., diabetic kidney disease); hyperglycemia or hyperinsulinemia; cancers with abnormal glycolipid synthesis; infectious diseases caused by the organisms using cell-surface glycolipids as a receptor; infectious diseases where the synthesis of glucosylceramide is essential or important; diseases in which excessive glycolipid synthesis occurs (e.g., atherosclerosis, polycystic kidney disease, and renal hypertrophy); neurological disorders and/or damages associated with the replenishment and activity of macrophages (e.g., Alzheimer's disease, epilepsy, stroke, spinal cord diseases, Parkinson's disease, etc.); inflammatory diseases or disorders (e.g., rheumatoid arthritis, Crohn's disease, asthma, sepsis); and diabetes and obesity (see, WO 2006/053043). And, overexpression of GCS interferes with ceramide-induced apoptosis (see, Liu Y Y, et al., Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance, J Biol Chem. 2000 Mar. 10; 275(10):7138-43). Therefore, GCS inhibitors may be useful for treating proliferative diseases, such as cancer, by inducing apoptosis in diseased cells.
Various studies have been conducted to develop GCS inhibitors. For example, various compounds having an inhibitory activity against GCS have been disclosed in WO 2005/068426, WO 2006/053043, WO 2008/150486, WO 2009/117150, WO 2010/014554, WO 2014/043068, etc.
The present inventors have found that a derivative having a 6,6-fused bicyclic moiety, i.e., a 1,2,3,4-tetrahydronaphthalene moiety, or pharmaceutically acceptable salt thereof has an excellent inhibitory activity against glucosylceramide synthase (GCS).
Therefore, the derivative having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Therefore, the present invention provides the above derivative having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof.
According to an aspect of the present invention, there is provided a derivative having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof.
According to another aspect of the present invention, there is provided a process for preparing said derivative having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof.
According to still another aspect of the present invention, there is provided a pharmaceutical composition comprising said derivative having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof as an active ingredient.
According to still another aspect of the present invention, there is provided a therapeutic method comprising administering said derivative having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof.
According to still another aspect of the present invention, there is provided a use of said derivative having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting glucosylceramide synthase.
It has been found by the present invention that the derivative having a 6,6-fused bicyclic moiety, i.e., a 1,2,3,4-tetrahydronaphthalene moiety, or pharmaceutically acceptable salt thereof has an excellent inhibitory activity against glucosylceramide synthase (GCS). Therefore, the compound or pharmaceutically acceptable salt thereof according to the present invention can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
As used herein, the term “alkyl” refers to a straight or branched aliphatic hydrocarbon radical. For example, the C1˜C6 alkyl means a straight or branched aliphatic hydrocarbon having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, neopentyl, and isopentyl.
The term “hydroxy” refers to the ‘—OH’ group. The term “alkoxy” refers to a radical formed by substituting the hydrogen atom in the hydroxyl group with an alkyl. For example, the C1˜C6 alkoxy includes methoxy, ethoxy, propoxy, n-butoxy, n-pentyloxy, isopropoxy, sec-butoxy, tert-butoxy, neopentyloxy, and isopentyloxy.
The term “halogen” refers to the fluoro, bromo, chloro, or iodo group.
The term “cycloalkyl” refers to a saturated aliphatic 3- to 10-membered ring, preferably 3- to 7-membered ring, unless otherwise defined. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, but are not limited thereto.
The term “aryl” refers to an organic radical derived from an aromatic hydrocarbon, through removing one hydrogen atom therefrom, including mono or poly-fused ring systems such as 5- to 14-membered substituted or unsubstituted rings and a form in which a plurality of aryls are connected by a single bond. The “aryl” includes, for example, phenyl, naphthyl, biphenyl, terphenyl, anthryl, indenyl, fluorenyl, phenanthryl, triphenylenyl, pyrenyl, perylenyl, chrysenyl, naphthacenyl, fluoranthenyl, and the like, but are not limited thereto.
The term “heteroaryl” refers to a 5- to 12-membered aromatic radical having one to three heteroatoms selected from the group consisting of nitrogen (N) atom, oxygen (O) atom, and sulfur (S) atom, including a 5- or 6-membered monocyclic heteroaryl radical and a bicyclic heteroaryl radical formed by fusing the 5- or 6-membered monocyclic heteroaryl radical with a benzene or pyridine ring. And, the term “heterocycle” refers to a 3- to 12-membered mono- or poly-cyclic ring having one or more, preferably one to four, same or different heteroatoms selected from oxygen (O) atom, nitrogen (N) atom, and sulfur (S) atom, but not containing an aromatic ring. Non-limiting examples of heteroaryl or heterocyclic rings include oxetane, pyrrolidine, pyrrole, tetrahydrofuran, furan, tetrahydrothiophene, thiophene, imidazolidine, imidazole, pyrazolidine, pyrazole, pyrrolizine, oxazolidine, oxazole, isoxazolidine, isoxazole, thiazolidine, thiazole, isothiazolidine, isothiazole, dioxolane, dithiolane, oxadiazole, thiadiazole, dithiazole, tetrazole, oxatetrazole, thiatetrazole, piperidine, pyridine, pyrimidine, tetrahydropyran, pyran, thiane, thiopyran, piperazine, diazine, morpholine, oxazine, dioxane, indole, indoline, benzodioxole, benzothiophene, benzofuran, benzimidazole, bezoxazole, benzisoxazole, benzothiazole, benzothiadiazole, benzotriazole, quinoline, isoquinoline, purine, furopyridine, mono- or di-azabicycles (such as quinuclidine, diazabicycloheptane, monoazabicyclooctane, diazaspiroundecane, etc.), hexahydropyrrolopyrrole, pyrrolopyrrole, pyrrolopyridine, imidazopyridazine, dihydrobenzodioxine, dihydrobenzofuran, and the like, but are not limited thereto.
The term “amino” refers to the ‘—NH2’ group. The term “alkylamino” refers to an amino group substituted with mono- or di-alkyl. For example, the C1˜C6 alkylamino group includes an amino group substituted with mono- or di-C1˜C6 alkyl group.
The term “alkylthio” refers to the ‘—SR’ group, in which R is an alkyl. The term “cyano” refers to the ‘—CN’.
The present invention provides a derivative having a 6,6-fused bicyclic moiety, i.e., a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, that is a compound of Formula 1 or pharmaceutically acceptable salt thereof:
wherein,
L is —O—, —CO—, —CR1R2—, or —NR3—,
R1 and R2 are, independently each other, hydrogen; halogen; C1˜C6 alkyl; C1˜C6 alkyl having a nitrogen, oxygen, or sulfur atom; C3˜C10 cycloalkyl; 3- to 12-membered heterocyclic; or C1˜C6 alkoxy,
R3 is hydrogen; C1˜C6 alkyl; C1˜C6 alkyl having a nitrogen, oxygen, or sulfur atom; C3˜C10 cycloalkyl; 3- to 12-membered heterocyclic; or C1˜C6 alkoxy,
X is hydrogen; halogen; C1˜C6 alkyl; C1˜C6 alkyl substituted with 1 to 3 halogens; C1˜C6 alkyl having a nitrogen, oxygen, or sulfur atom; C1˜C6 alkoxy; or C1˜C6 alkoxy substituted with 1 to 3 halogens,
Y, Q and Z are, independently each other, —CR4R5—,
R4 and R5 are, independently each other, hydrogen; halogen; C1˜C6 alkyl; C1˜C6 alkyl having a nitrogen, oxygen, or sulfur atom; C3˜C10 cycloalkyl; 3- to 12-membered heterocyclic; or C1˜C6 alkoxy; or R4 and R5 form C3˜C10 cycloalkyl together with the carbon atom of Y, Q or Z to which they are attached,
W is a bond, —CH2—, —O—, —NH—, —CH2CH2—, —CH═CH—, or —C≡C—,
A ring is 6- to 12-membered aryl; 5- to 12-membered heteroaryl; C3˜C10 cycloalkyl; or 3- to 12-membered heterocyclic, and
X1, X2, X3, and X4 are, independently each other, hydrogen; cyano; halogen; C1˜C6 alkyl; C1˜C6 alkyl substituted with 1 to 3 halogens; C3˜C10 cycloalkyl; 3- to 12-membered heterocyclic; C1˜C6 alkoxy; C1˜C6 alkoxy-C1˜C6 alkoxy; C1˜C6 alkoxy substituted with 1 to 3 halogens; C1˜C6 alkylthio; morpholinyl; amino; mono- or di-C1˜C6 alkylamino; C1˜C6 alkylcarbonyl; hydroxy; or nitro.
In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, L may be —O—.
In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, X may be hydrogen; halogen; or C1˜C6 alkoxy.
In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, R4 and R5 may be, independently each other, hydrogen or C1˜C6 alkyl; or may form C3˜C10 cycloalkyl together with the carbon atom of Y, Q or Z to which they are attached. In an embodiment, Y may be —CH2—. In another embodiment, Q may be —CH2—. In still another embodiment, Y may be —CH2—; Q may be —CH2—; and Z may be —CR4R5—; and R4 and R5 may be, independently each other, hydrogen or C1˜C6 alkyl or may form be C3˜C10 cycloalkyl together with the carbon atom of Z.
In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, W may be a bond (i.e., the A ring is directly bound to the 1,2,3,4-tetrahydronaphthalene moiety).
In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, the A ring may be phenyl, benzodioxolyl, 2,3-dihydrobenzodioxinyl, 2,3-dihydrobenzofuranyl, pyridinyl, pyrrolo[2.3-b]pyridinyl, pyrimidinyl, or thiophenyl.
In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, X1, X2, X3, and X4 may be, independently each other, hydrogen; cyano; halogen; C1˜C6 alkyl; C1˜C6 alkyl substituted with 1 to 3 halogens; C3˜C10 cycloalkyl; C1˜C6 alkoxy; C1˜C6 alkoxy-C1˜C6 alkoxy; C1˜C6 alkoxy substituted with 1 to 3 halogens; morpholinyl; mono- or di-C1˜C6 alkylamino; or C1˜C6 alkylcarbonyl.
In a preferred embodiment of the present invention,
L is —O—,
X is hydrogen; halogen; or C1˜C6 alkoxy,
R4 and R5 are, independently each other, hydrogen or C1˜C6 alkyl; or R4 and R5 form C3˜C10 cycloalkyl together with the carbon atom of Y, Q or Z to which they are attached,
W is a bond,
A ring is phenyl, benzodioxolyl, 2,3-dihydrobenzodioxinyl, 2,3-dihydrobenzofuranyl, pyridinyl, pyrrolo[2.3-b]pyridinyl, pyrimidinyl, or thiophenyl, and
X1, X2, X3, and X4 are, independently each other, hydrogen; cyano; halogen; C1˜C6 alkyl; C1˜C6 alkyl substituted with 1 to 3 halogens; C3˜C10 cycloalkyl; C1˜C6 alkoxy; C1˜C6 alkoxy-C1˜C6 alkoxy; C1˜C6 alkoxy substituted with 1 to 3 halogens; morpholinyl; mono- or di-C1˜C6 alkylamino; or C1˜C6 alkylcarbonyl.
In said embodiment, Y may be —CH2—.
In said embodiment, Q may be —CH2—.
In said embodiment, Y may be —CH2—; Q may be —CH2—; and Z may be —CR4R5—; and R4 and R5 may be, independently each other, hydrogen or C1˜C6 alkyl or may form be C3˜C10 cycloalkyl together with the carbon atom of Z.
In the compound of Formula 1 or pharmaceutically acceptable salt, preferable compounds include a compound, including a pharmaceutically acceptable salt thereof, selected from the group consisting of:
The compound of Formula 1 or pharmaceutically acceptable salt thereof may be in the form of cis- or trans-geometrical isomer. The compound of Formula 1 or its pharmaceutically acceptable salt comprises both cis- and trans-geometrical isomers, unless otherwise indicated. The compound of Formula 1 or pharmaceutically acceptable salt thereof may also have substituents containing asymmetric atom and therefore be in the form of racemic mixture (RS) or in the form of an optical isomer, such as (R) or (S) isomer. The compound of Formula 1 or pharmaceutically acceptable salt thereof comprises both the racemic mixture (RS) and each optical isomer such as (R) or (S) isomer, unless otherwise indicated. In addition, the compound of Formula 1 or pharmaceutically acceptable salt thereof may have two or more chiral centers and therefore be in the form of one or more diastereomers or in the form of the mixture thereof. The compound of Formula 1 or pharmaceutically acceptable salt thereof comprises both each diastereomer and the mixture thereof, unless otherwise indicated.
The compound of Formula 1 of the present invention may be in a pharmaceutically acceptable salt form. The salt may be a conventional acid addition salt form, which includes e.g., salts derived from an inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, or hydrobromic acid; and salts derived from an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, benzoic acid, citric acid, maleic acid, malonic acid, malic acid, tartaric acid, gluconic acid, lactic acid, gentisic acid, fumaric acid, lactobionic acid, salicylic acid, phthalic acid, embonic acid, aspartic acid, glutamic acid, or acetylsalicylic acid. And, the salt also includes, e.g., salts derived from an amino acid such as glycine, alanine, valine, isoleucine, serine, cysteine, cystine, aspartic acid, glutamine, lysine, arginine, tyrosine, or proline. In addition, the salt includes, e.g., salts derived from a sulfonic acid such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, or toluenesulfonic acid.
The compound of Formula 1 or pharmaceutically acceptable salt thereof according the present invention may be prepared according to various methods.
For example, the compound of Formula 1a or pharmaceutically acceptable salt thereof according the present invention may be prepared by a process which comprises reacting a compound of Formula 2 or salt thereof with ethyl chloroformate to obtain a compound of Formula 3; coupling the compound of Formula 3 with a compound of Formula 4 to obtain a compound of Formula 5; reacting the compound of Formula 5 with a A-W-boronic acid substituted with X1, X2, X3, or X4 to obtain a compound of Formula 1a; and optionally converting the compound of Formula 1a to a pharmaceutically acceptable salt thereof, as shown in the following Reaction Scheme 1.
In the Reaction Scheme 1, X, Y, Q, Z, W, A ring, X1, X2, X3, and X4 are the same as defined in the above.
The compound of Formula 2, which is commercially available or a known compound, may be synthesized according to literatures. The reaction between the compound of Formula 2 or salt thereof and ethyl chloroformate may be carried out in the presence of an organic base such as triethylamine, N,N-diisopropylethylamine, etc. or an inorganic base such as potassium carbonate, etc. The base may be used in an amount ranging from 1 to 1.5 equivalents based on 1 equivalent of the compound of Formula 2 or in an amount ranging from 3 to 5 equivalents based on 1 equivalent of the salt of the compound of Formula 2 (e.g., hydrochloride). The reaction may be carried out in a solvent such as dichloromethane or tetrahydrofuran preferably at 0° C. to room temperature.
The coupling between the compound of Formula 3 and the compound of Formula 4 (i.e., quinuclidinol) may be carried out through a condensation reaction including the removal of ethanol. The reaction may be carried out preferably in the presence of a base such as sodium hydride. In addition, the reaction may be carried out in a non-polar organic solvent such as toluene at 120° C. to 140° C.
The reaction between the compound of Formula 5 and the A-W-boronic acid substituted with X1, X2, X3, or X4 may be carried out according to the Suzuki reaction. Said Suzuki reaction may be carried out using a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4), palladium(II) acetate (Pd(OAc)2), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)C12), etc. In addition, said Suzuki reaction may be carried out in the presence of an inorganic base such as cesium carbonate (Cs2CO3), sodium carbonate (Na2CO3), potassium carbonate (K2CO3), potassium phosphate (K3PO4), etc. Said Suzuki reaction may be carried out in a non-polar organic solvent such as toluene or a polar organic solvent such as 1,4-dioxane, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, or N,N-dimethylformamide, at 50° C. to 150° C., preferably 80° C. to 120° C. Other reaction conditions including a reaction time may be determined according to known methods for the Suzuki reaction.
The conversion of the compound of Formula 1a to a pharmaceutically acceptable salt thereof may be carried out according to conventional methods. For example, a pharmaceutically acceptable salt of the compound of Formula 1a may be prepared by dissolving the compound of Formula 1a in a water-miscible solvent such as methanol, ethanol, acetone or 1,4-dioxane and then added a free acid or a free base thereto for the crystallization thereof.
In addition, the compound of Formula 1a or pharmaceutically acceptable salt thereof according the present invention may be prepared by a process which comprises reacting a compound of Formula 4 with bis(4-nitrophenyl) carbonate to obtain a compound of Formula 7; reacting the compound of Formula 7 with a compound of Formula 2 to obtain a compound of Formula 5; reacting the compound of Formula 5 with a A-W-boronic acid substituted with X1, X2, X3, or X4 to obtain a compound of Formula 1a; and optionally converting the compound of Formula 1a to a pharmaceutically acceptable salt thereof, as shown in the following Reaction Scheme 2.
In the Reaction Scheme 2, X, Y, Q, Z, W, A ring, X1, X2, X3, and X4 are the same as defined in the above.
The reaction between the compound of Formula 4 (i.e., quinuclidinol) and bis(4-nitrophenyl) carbonate may be carried out in a polar solvent such as N,N-dimethylformamide preferably at 0° C. to 25° C. The compound of Formula 7 may be also prepared by reacting the compound of Formula 4 with 4-nitrophenyl chloroformate, in the presence of a base such as triethylamine, in a solvent such as dichloromethane, acetonitrile, etc.
The reaction between the compound of Formula 7 and the compound of Formula 2 may be carried out in a solvent such as N,N-dimethylformamide, tetrahydrofuran or acetonitrile, in the presence of a base such as N,N-diisopropylethylamine or triethylamine, at 0° C. to 25° C.
The reaction between the compound of Formula 5 and the A-W-boronic acid substituted with X1, X2, X3, or X4 may be carried out according to the Suzuki reaction, as described in the above. In addition, the conversion of the compound of Formula 1a to a pharmaceutically acceptable salt thereof may be carried out according to conventional methods, as described in the above.
The compound having a 1,2,3,4-tetrahydronaphthalene moiety according to the present invention, i.e., the compound of Formula 1 or pharmaceutically acceptable salt thereof has an excellent inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating treating various diseases associated with GCS.
Therefore, the present invention includes, within its scope, a pharmaceutical composition for inhibiting glucosylceramide synthase (GCS), comprising a therapeutically effective amount of the compound of Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In an embodiment, the present invention provides a pharmaceutical composition for preventing or treating the diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc., comprising a therapeutically effective amount of the compound of Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier, such as diluents, disintegrants, sweeteners, lubricants, or flavoring agents. The pharmaceutical composition may be formulated to an oral dosage form such as tablets, capsules, powders, granules, suspensions, emulsions, or syrups; or a parenteral dosage form such as solutions for external use, suspensions for external use, emulsions for external use, gels (e.g., ointment), inhalations, nebulizations, injections. The dosage form may be various forms, e.g., dosage forms for single administration or for multiple administrations.
The pharmaceutical composition of the present invention may comprise, for example, a diluent (e.g., lactose, corn starch, etc.); a lubricant (e.g., magnesium stearate); an emulsifying agent; a suspending agent; a stabilizer; and/or an isotonic agent. If necessary, the composition further comprises sweeteners and/or flavoring agents.
The composition of the present invention may be administered orally or parenterally, including inhalant, intravenous, intraperitoneal, subcutaneous, rectal and topical routes of administration. Therefore, the composition of the present invention may be formulated into various forms such as tablets, capsules, aqueous solutions or suspensions. In the case of tablets for oral administration, carriers such as lactose, corn starch, and lubricating agents, e.g. magnesium stearate, are conventionally used. In the case of capsules for oral administration, lactose and/or dried corn starch can be used as a diluent. When an aqueous suspension is required for oral administration, the active ingredient may be combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring agents may be used. For intramuscular, intraperitoneal, subcutaneous and intravenous administration, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous administration, the total concentration of solutes should be controlled in order to render the preparation isotonic. The composition of the present invention may be in the form of an aqueous solution containing pharmaceutically acceptable carriers, e.g., saline having a pH level of 7.4. The solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.
The compound of Formula 1 or pharmaceutically acceptable salt thereof may be administered in a therapeutically effective amount ranging from about 0.0001 mg/kg to about 100 mg/kg per day to a subject patient. Of course, the dosage may be changed according to the patient's age, weight, susceptibility, symptom, or activity of the compound.
The present invention includes, within its scope, a method for inhibiting glucosylceramide synthase (GCS) in a mammal, comprising administering a therapeutically effective amount of the compound of Formula 1 or pharmaceutically acceptable salt thereof to the mammal in need thereof. In an embodiment, the present invention provides a method for treating the diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc., comprising administering a therapeutically effective amount of the compound of Formula 1 or pharmaceutically acceptable salt thereof to the mammal in need thereof.
The present invention also provides a use of the compound of Formula 1 or pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting glucosylceramide synthase (GCS) in a mammal. In an embodiment, the present invention provides a use of the compound of Formula 1 or pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or treating the diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
The following examples and experimental examples are provided for illustration purposes only, and are not intended to limit the scope of the invention.
In the following examples, brine refers to a saturated aqueous sodium chloride solution. Unless otherwise indicated, all temperatures are in degrees Celsius (° C.). All reactions were carried out at room temperature unless otherwise indicated.
The analyses of the compounds prepared in the following Preparations and Examples were carried out as follows: Nuclear magnetic resonance (NMR) spectrum analysis was carried out using Bruker 400 MHz spectrometer and chemical shifts thereof were analyzed in ppm. Column chromatography was carried out on silica gel (Merck, 70-230 mesh). Each starting material is a known compound which was synthesized according to literatures or purchased commercially. All reactions and chromatographic fractions were analyzed by thin layer chromatography (TLC) on a 250 nm silica gel plate and visualized with ultraviolet or iodine (12) staining.
6-Bromo-1,2,3,4-tetrahydronaphthalen-1-amine (20 g, 82.6 mmol) was dissolved in dichloromethane (250 mL) and then triethylamine (12.7 ml, 90.9 mmol) and ethyl chloroformate (8.7 ml, 90.9 mmol) were slowly added thereto. The reaction mixture was stirred at room temperature for 4 hours. Water was added to the reaction mixture, which was then extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (n-hexane/ethyl acetate=1/1, v/v) to give the titled compound as a white solid. (20.7 g, Yield: 83%)
1H-NMR (400 MHz, CDCl3) δ 7.31˜7.21 (m, 3H), 4.85 (s, 1H), 4.18 (m, 2H), 2.76 (m, 2H), 2.06 (m, 1H), 1.83 (m, 3H), 1.28 (t, 3H)
(S)-(+)-3-Quinuclidinol (25.6 g, 201.2 mmol) was dissolved in toluene (200 ml) and then sodium hydride (1.6 g, 67.1 mmol) was added thereto at 0° C. The reaction mixture was stirred for 15 minutes and then ethyl (6-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate (20 g, 67.1 mmol) prepared in Step 1 was added thereto. The reaction mixture was refluxed under stirring at 140° C. for 21 hours and then cooled to room temperature. Brine was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with brine two times, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate/(methanol/ammonia water=1/1)=9/1, v/v) to give the titled compound as a white solid. (17 g, Yield: 66%)
1H-NMR (400 MHz, CDCl3) δ 7.31˜7.19 (m, 3H), 5.08 (m, 1H), 4.85 (m, 1H), 4.77 (br, 1H), 3.24 (m, 1H), 2.84 (m, 2H), 2.74 (m, 4H), 2.10˜2.05 (m, 3H), 1.83 (m, 4H), 1.69 (m, 1H), 1.58 (m, 1H), 1.38 (m, 1H)
The titled compound was prepared in accordance with the same procedures as in Preparation 1, using 7-bromo-1,2,3,4-tetrahydronaphthalen-1-amine as a starting material.
1H-NMR (400 MHz, CDCl3) δ 7.39 (d, 1H), 7.28 (d, 1H), 7.02 (d, 1H), 4.76 (s, 2H), 3.26 (q, 1H), 2.87˜2.71 (m, 7H), 2.11˜1.88 (m, 4H), 1.85˜1.72 (m, 3H), 1.70˜1.61 (bs, 1H), 1.56˜1.46 (m, 1H)
6-Bromo-1,2,3,4-tetrahydronaphthalen-1-one (20 g, 88.9 mmol) was dissolved in tetrahydrofuran (70 ml) and then 60% sodium hydride (17.8 g, 444.3 mmol) was added thereto at 0° C. The reaction mixture was stirred for 15 minutes and then iodomethane (22.1 ml, 355.4 mmol) was slowly added thereto at the same temperature. The reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (n-hexane/ethyl acetate=10/1, v/v) to give the titled compound as a white solid. (20 g, Yield: 90%)
1H-NMR (400 MHz, CDCl3) δ 8.03 (d, 1H), 7.74 (d, 1H), 7.21 (t, 1H), 3.00 (m, 2H), 2.01 (m, 2H), 1.22 (s, 6H)
6-Bromo-2,2-dimethyl-1,2,3,4-tetrahydronaphthalen-1(2H)-one (20 g, 79.0 mmol) prepared in Step 1 was dissolved in methanol (300 ml) and then ammonium acetate (121.8 g, 1580.1 mmol) and sodium cyanoborohydride (24.8 g, 395.0 mmol) were added thereto. The reaction mixture was stirred at room temperature for 4 hours and then refluxed under stirring at 80° C. for 12 hours. The reaction mixture was cooled to room temperature, basified to pH>12 with a 1N sodium hydroxide solution, and then extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. Ethyl acetate was added to the resulting residue and then a hydrochloric acid solution (4M) in 1,4-dioxane was added thereto. The mixture was stirred at room temperature for 1 hour. The resulting solid was filtered under reduced pressure, washed with ethyl acetate, and then dried to give the titled compound as a white solid. (12 g, Yield: 52%)
1H-NMR (400 MHz, CD3OD) δ 7.68 (d, 1H), 7.41 (d, 1H), 7.25 (t, 1H), 4.13 (s, 1H), 2.96 (m, 1H), 2.75 (m, 1H), 1.88 (m, 1H), 1.75 (m, 1H), 1.20 (s, 3H), 1.03 (s, 3H)
A solution of (S)-(+)-3-quinuclidinol (6.3 g, 49.5 mmo) and bis(4-nitrophenyl) carbonate (15.1 g, 49.5 mmol) in N,N-dimethylformamide (80 mL) was stirred at room temperature for 8 hours. {{99.Solvent volume:row 1}}_XXXXX_ 0
6-Bromo-2,2-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride (20 g, 41.3 mmol) prepared in Step 2 and {{99.Reactant volume or quant:row 2}}_XXXXX_diisopropylethylamine (21.6 mL, 123.9 mmol) were added to the solution, which was then stirred at room temperature overnight. The reaction mixture was extracted with diisopropyl ether (100 ml×2). The aqueous layer was basified to pH 12 with ammonia and then extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate/(methanol/ammonia water=1/1)=9/1, v/v) to give the titled compound as a white solid. (6 g, Yield: 36%)
1H-NMR (400 MHz, CDCl3) δ 7.25 (m, 2H), 7.12 (m, 1H), 5.09 (m, 1H), 4.95 (m, 1H), 4.53 (m, 1H), 3.20 (m, 1H), 2.84˜2.65 (m, 7H), 1.95 (m, 1H), 1.81 (m, 2H), 1.66 (br, 1H), 1.53 (br, 1H), 1.38 (br, 1H), 0.99 (m, 3H), 0.88 (m, 3H)
The titled compound was prepared in accordance with the same procedures as in Step 1 of Preparation 3, using 7-bromo-3,4-dihydronaphthalen-1(2H)-one as a starting material.
1H-NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.57 (d, 1H), 7.12 (d, 1H), 2.94 (m, 2H), 1.99 (m, 2H), 1.27 (s, 6H)
The titled compound was prepared in accordance with the same procedures as in Step 2 of Preparation 3, using 7-bromo-2,2-dimethyl-1,2,3,4-tetrahydronaphthalen-1(2H)-one prepared in Step 1.
1H-NMR (400 MHz, MeOD) δ 7.60 (s, 1H), 7.51 (d, 1H), 7.20 (d, 1H), 4.09 (s, 1H), 3.88 (m, 2H), 1.87 (m, 1H), 1.70 (m, 1H), 1.16 (s, 3H), 1.05 (s, 3H)
The titled compound was prepared in accordance with the same procedures as in Step 1 of Preparation 1, using 7-bromo-2,2-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride prepared in Step 2. The product was used in subsequent reaction without further purification.
The titled compound was prepared in accordance with the same procedures as in Step 2 of Preparation 1, using ethyl (7-bromo-2,2-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate prepared in Step 3.
1H-NMR (400 MHz, CDCl3) δ 7.40 (m, 1H), 7.25 (m, 1H), 6.95 (d, 1H), 5.09 (m, 1H), 4.78 (m, 1H), 4.59 (m, 1H), 3.22 (m, 1H), 2.86˜2.68 (m, 7H), 1.98 (m, 1H), 1.82 (m, 2H), 1.66 (m, 1H), 1.55 (m, 1H), 1.38 (m, 1H), 1.00 (m, 3H), 0.88 (m, 3H)
A solution of 2-chloroethyl methyl sulfide (10 g, 90.4 mmol) in iodomethane (50 ml) was stirred at room temperature for 2 days. The resulting solid was filtered under reduced pressure, washed with acetone, and then dried to give the titled compound. (16 g, Yield: 70%) The product was used in subsequent reaction without further purification.
6-Bromo-3,4-hydronaphthalen-1(2H)-one (1.03 g, 4.58 mmol) was dissolved in tert-butanol (10 mL) and then sodium iodide (0.131 g, 0.872 mmol) and 60% sodium hydride (0.349 g, 8.72 mmol) were slowly added thereto. The reaction mixture was stirred at room temperature for 20 minutes. (2-Chloroethyl)dimethylsulfonium iodide (1.10 g, 4.36 mmol) prepared in Step 1 was slowly added over 1 hour to the reaction mixture, which was then stirred at room temperature overnight. The reaction was quenched by adding water (15 ml) to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (n-hexane/ethyl acetate=10/1, v/v) to give the titled compound as a white solid. (789 mg, Yield: 78%)
1H-NMR (400 MHz, CDCl3) δ 7.99 (d, 1H), 7.73 (d, 1H), 7.19 (t, 1H), 3.08 (m, 2H), 1.99 (m, 2H), 1.40 (d, 2H), 0.86 (d, 2H)
The titled compound was prepared in accordance with the same procedures as in Step 2 of Preparation 3, using 6′-bromo-3′,4′-dihydro-1′H-spiro[cyclopropane-1,2′-naphthalen]-1′-one prepared in Step 2.
1H-NMR (400 MHz, MeOD) δ 7.67 (d, 1H), 7.37 (d, 1H), 7.23 (t, 1H), 3.68 (s, 1H), 3.09 (m, 1H), 2.82 (m, 1H), 2.39 (m, 1H), 1.26 (m, 1H), 0.93 (m, 1H), 0.79 (m, 1H), 0.69 (m, 1H), 0.55 (m, 1H)
The titled compound was prepared in accordance with the same procedures as in Step 1 of Preparation 1, using 6′-bromo-3′,4′-dihydro-1′H-spiro[cyclopropane-1,2′-naphthalen]-1′-amine hydrochloride prepared in Step 3. The product was used in subsequent reaction without further purification.
1H-NMR (400 MHz, CDCl3) δ 7.48 (d, 1H), 7.30 (m, 1H), 7.06 (t, 1H), 4.98 (br, 1H), 4.27 (d, 1H), 4.15 (m, 2H), 2.95 (m, 1H), 2.74 (m, 1H), 2.03 (m, 1H), 1.31 (m, 1H), 1.27 (m, 3H), 0.85 (m, 1H), 0.50 (m, 1H), 0.45 (s, 2H)
The titled compound was prepared in accordance with the same procedures as in Step 2 of Preparation 1, using ethyl (6′-bromo-3′,4′-dihydro-1′H-spiro[cyclopropane-1,2′-naphthalen]-1′-yl)carbamate prepared in Step 4.
1H-NMR (400 MHz, CDCl3) δ 7.47 (d, 2H), 7.27 (m, 1H), 7.04 (m, 1H), 5.30 (m, 1H), 4.78˜4.76 (m, 2H), 4.23 (d, 1H), 3.23 (m, 1H), 2.86˜2.67 (m, 7H), 2.42 (br, 1H), 1.98 (m, 1H), 1.83 (m, 1H), 1.67 (m, 1H), 1.55 (m, 1H), 1.37 (m, 1H), 0.85 (m, 1H), 0.47˜0.44 (m, 2H)
The titled compound was prepared in accordance with the same procedures as in Preparation 5, using 7-bromo-3,4-hydronaphthalen-1(2H)-one as a starting material.
1H-NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 7.30 (m, 1H), 6.99 (d, 1H), 5.42 (br, 1H), 4.77 (m, 2H), 4.26 (m, 1H), 3.22 (m, 1H), 2.85˜2.67 (m, 7H), 2.10 (br, 1H), 1.98 (m, 1H), 1.83 (br, 1H), 1.67 (br, 1H), 1.55 (br, 1H), 1.39 (br, 1H), 0.85 (m, 1H), 0.51 (m, 1H), 0.49 (m, 2H)
The titled compound was prepared in accordance with the same procedures as in Preparation 3, using 6-bromo-7-fluoro-3,4-hydronaphthalen-1(2H)-one as a starting material.
1H-NMR (400 MHz, CDCl3) δ 7.29 (m, 2H), 7.04 (m, 1H), 4.78 (m, 2H), 4.56 (d, 1H), 3.25 (m, 1H), 2.93˜2.74 (m, 7H), 2.09 (br, 1H), 1.82 (br, 1H), 1.71 (br, 3H), 1.59 (br, 1H), 1.42 (br, 1H), 1.03 (d, 3H), 0.91 (d, 3H)
The titled compound was prepared in accordance with the same procedures as in Preparation 3, using 6-bromo-7-methoxy-3,4-hydronaphthalen-1(2H)-one as a starting material.
1H-NMR (400 MHz, CDCl3) δ 7.27 (m, 2H), 6.79 (m, 1H), 4.77 (m, 2H), 4.55 (d, 1H), 3.84 (d, 3H), 3.25 (m, 1H), 2.93˜2.74 (m, 7H), 2.09 (br, 1H), 1.89 (br, 1H), 1.71 (br, 3H), 1.56 (br, 1H), 1.41 (br, 1H), 1.03 (d, 3H), 0.95 (d, 3H)
To a mixture of (S)-quinuclidin-3-yl-(6-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate (30 mg, 0.079 mmol) prepared in Preparation 1, 4-fluorophenylboronic acid (16.6 mg, 0.12 mmol), potassium phosphate (50.4 mg, 0.23 mmol), and tetrakis(triphenylphosphine)palladium(0) (9.1 mg, 10 mol %), were slowly added 1,4-dioxane (1 ml) and water (0.5 ml). The reaction mixture was refluxed under stirring at 120° C. overnight and then cooled to room temperature. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. The resulting residue in the yellow oil form was purified by silica gel column chromatography (ethyl acetate/(methanol/ammonia water=1/1)=9/1, v/v) to give the titled compound as a white solid. (20 mg, Yield: 65%)
1H-NMR (400 MHz, CDCl3) δ 7.53 (m, 2H), 7.39 (m, 2H), 7.26 (m, 1H), 7.13 (m, 2H), 5.02 (m, 2H), 4.80 (m, 1H), 3.27 (m, 1H), 2.87˜2.77 (m, 7H), 2.08 (m, 2H), 1.89 (m, 4H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
The titled compounds of Examples 2 to 54 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (6-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate prepared in Preparation 1; and the corresponding substituted-boronic acids, respectively.
1H-NMR (400 MHz, CDCl3) δ 7.51 (m, 2H), 7.42 (m, 3H), 7.29 (m, 2H), 5.00 (m, 2H), 4.81 (br, 1H), 3.30 (m, 1H), 2.87˜2.77 (m, 7H), 2.06 (m, 2H), 1.89 (m, 4H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.69 (s, 3H), 7.45 (m, 2H), 7.35 (m, 1H), 7.28 (d, 1H), 4.99 (m, 2H), 4.80 (br, 1H), 3.29 (m, 1H), 2.88˜2.77 (m, 7H), 2.14 (m, 2H), 1.91 (m, 4H), 1.71 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.57 (d, 1H), 7.42 (m, 4H), 7.28 (m, 2H), 5.00 (m, 2H), 4.80 (br, 1H), 3.28 (m, 1H), 2.86˜2.77 (m, 7H), 2.08 (m, 2H), 1.90 (m, 4H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.46˜7.36 (m, 4H), 7.30˜7.28 (m, 2H), 7.04 (t, 1H), 5.00 (m, 2H), 4.80 (m, 1H), 3.28 (m, 1H), 2.88˜2.77 (m, 7H), 2.13 (m, 2H), 1.89 (m, 4H), 1.71 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.56 (s, 1H), 7.44 (m, 1H), 7.37 (m, 2H), 7.23 (m, 2H), 5.00 (m, 2H), 4.80 (br, 1H), 3.28 (m, 1H), 2.88˜2.77 (m, 7H), 2.09 (m, 2H), 1.90˜1.82 (m, 4H), 1.71 (br, 1H), 1.60 (m, 1H), 1.41 (m, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.81 (s, 1H), 7.76 (d, 1H), 7.62˜7.54 (m, 2H), 7.44 (m, 2H), 7.34 (s, 1H), 5.06˜5.03 (m, 2H), 4.81 (br, 1H), 3.28 (m, 1H), 2.88˜2.74 (m, 7H), 2.12 (m, 2H), 1.90 (m, 3H), 1.83 (br, 1H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.50˜7.41 (m, 5H), 7.31 (s, 1H), 7.22 (m, 1H), 5.06˜5.04 (m, 2H), 4.80 (br, 1H), 3.27 (m, 1H), 2.87˜2.77 (m, 7H), 2.08 (m, 2H), 1.90 (m, 3H), 1.82 (br, 1H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.44 (m, 3H), 7.34 (m, 2H), 7.23 (m, 1H), 7.18 (m, 1H), 5.03 (m, 1H), 4.97 (br, 1H), 4.80 (br, 1H), 3.28 (m, 1H), 2.86˜2.77 (m, 7H), 2.06 (m, 2H), 1.90 (m, 4H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 1H), 7.66 (m, 1H), 7.44 (m, 4H), 7.18 (s, 1H), 5.08 (m, 1H), 4.98 (br, 1H), 4.81 (br, 1H), 3.28 (m, 1H), 2.90˜2.78 (m, 7H), 2.13 (m, 1H), 1.90 (m, 5H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.74 (m, 1H), 7.56 (m, 1H), 7.55 (, 1H), 7.47 (br, 1H), 7.32 (m, 1H), 7.16 (br, 1H), 7.07 (s, 1H), 5.07 (m, 1H), 4.96 (m, 1H), 4.80 (m, 1H), 3.29 (m, 1H), 2.88˜2.81 (m, 7H), 2.09 (m, 2H), 1.90 (m, 4H), 1.71 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.41˜7.37 (m, 4H), 7.31 (m, 2H), 7.20 (s 1H), 5.08 (m, 1H), 4.97 (br, 1H), 4.81 (m, 1H), 3.30 (m, 1H), 2.86˜2.78 (m, 7H), 2.14 (m, 2H), 1.90 (m, 4H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.55 (d, 2H), 7.40 (m, 2H), 7.29 (s, 1H), 7.18 (d, 2H), 6.74˜6.37 (t, 1H), 5.18 (m, 1H), 4.95 (m, 1H), 4.79 (m, 1H), 3.27 (m, 1H), 2.86˜2.72 (m, 7H), 2.08 (m, 2H), 1.88 (m, 3H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.49 (d, 2H), 7.42 (d, 2H), 7.32 (s, 1H), 7.27 (m, 3H), 4.99 (m, 2H), 4.79 (br, 1H), 3.30 (m, 1H), 2.87˜2.78 (m, 7H), 2.41 (s, 3H), 2.08 (m, 2H), 1.89 (m, 3H), 1.82 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.43 (m, 1H), 7.37 (m, 2H), 7.26 (m, 2H), 7.21 (m, 1H), 4.98 (m, 1H), 4.96 (m, 1H), 4.80 (br, 1H), 3.30 (m, 1H), 2.87˜2.78 (m, 7H), 2.09 (m, 2H), 1.89 (m, 3H), 1.81 (m, 2H), 1.71 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.45 (m, 1H), 7.37 (m, 1H), 7.12 (m, 2H), 7.00 (m, 1H), 5.02 (m, 2H), 4.81 (m, 1H), 3.31 (m, 1H), 2.87˜2.78 (m, 7H), 2.06 (m, 2H), 1.89 (m, 4H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.45 (m, 1H), 7.39 (m, 1H), 7.29 (m, 1H), 7.10 (d, 2H), 6.79 (m, 1H), 5.00 (m, 1H), 4.96 (m, 1H), 4.81 (br, 1H), 3.30 (m, 1H), 2.87˜2.77 (m, 7H), 2.13 (m, 2H), 1.89 (m, 4H), 1.71 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.43 (m, 2H), 7.32 (m, 1H), 7.24 (s, 1H), 6.94 (m, 2H), 5.00 (m, 1H), 4.96 (br, 1H), 4.79 (br, 1H), 3.30 (m, 1H), 2.86˜2.77 (m, 7H), 2.14 (m, 2H), 1.89˜1.83 (m, 4H), 1.70 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.45 (t, 1H), 7.37 (br, 1H), 7.28 (m, 1H), 7.15 (m, 3H), 5.01 (m, 1H), 4.97 (m, 1H), 4.81 (br, 1H), 3.30 (m, 1H), 2.86˜2.75 (br, 7H), 2.13 (m, 2H), 1.90 (m, 2H), 1.82 (m, 2H), 1.71 (br, 1H), 1.59 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.45 (t, 1H), 7.32 (m, 1H), 7.24 (s, 1H), 7.14 (m, 1H), 7.05 (m, 1H), 5.01 (m, 2H), 4.80 (br, 1H), 3.30 (m, 1H), 2.87˜2.78 (m, 7H), 2.14 (m, 2H), 1.90 (m, 2H), 1.80 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.46 (m, 1H), 7.31 (m, 1H), 7.25 (m, 2H), 7.02 (t, 1H), 5.00 (m, 2H), 4.80 (br, 1H), 3.28 (m, 1H), 2.86˜2.73 (m, 7H), 2.14 (m, 2H), 1.89 (m, 2H), 1.82 (m, 2H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.66 (m, 1H), 7.51˜7.49 (m, 2H), 7.41 (m, 3H), 4.99 (m, 2H), 4.80 (br, 1H), 3.30 (m, 1H), 2.87˜2.78 (m, 7H), 2.13 (m, 2H), 1.90 (m, 2H), 1.82 (m, 2H), 1.71 (br, 1H), 1.61 (br, 1H), 1.42 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.42 (m, 2H), 7.32 (s, 1H), 7.26 (m, 2H), 7.15 (s, 1H), 5.05 (m, 1H), 4.97 (m, 1H), 4.81 (br, 1H), 3.28 (m, 1H), 2.88˜2.77 (m, 7H), 2.13 (m, 2H), 1.90˜1.87 (m, 4H), 1.70 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.57 (m, 1H), 7.49 (m, 1H), 7.44 (s, 2H), 7.36 (m, 1H), 7.34 (m, 1H), 5.00 (m, 2H), 4.81 (br, 1H), 3.28 (m, 1H), 2.87˜2.78 (m, 7H), 2.13 (m, 2H), 1.90 (m, 2H), 1.84 (m, 2H), 1.71 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.51 (d, 2H), 7.40 (m, 2H), 7.28 (m, 1H), 7.01 (d, 2H), 5.02 (m, 1H), 4.95˜4.81 (m, 2H), 4.19 (d, 2H), 3.81 (d, 2H), 3.79 (s, 3H), 3.30 (m, 1H), 2.90˜2.80 (m, 7H), 2.06 (m, 4H), 1.99 (m, 2H), 1.73 (br, 1H), 1.63 (br, 1H), 1.44 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.51 (m, 2H), 7.40 (m, 2H), 7.28 (m, 1H), 7.12 (d, 2H), 5.23 (s, 2H), 5.07 (m, 1H), 4.94˜4.80 (m, 2H), 3.52 (s, 3H), 3.29 (m, 1H), 2.86˜2.78 (m, 7H), 2.06 (m, 2H), 1.88 (m, 4H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.42 (m, 2H), 7.37 (m, 2H), 7.18 (m, 2H), 6.94 (d, 1H), 5.02 (m, 1H), 4.95˜4.82 (m, 2H), 4.21 (d, 2H), 3.80 (d, 2H), 3.80 (s, 3H), 3.31 (m, 1H), 2.91˜2.81 (m, 7H), 2.31 (br, 2H), 2.12 (m, 2H), 1.89 (m, 2H), 1.73 (br, 1H), 1.62 (br, 1H), 1.44 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.41 (d, 2H), 7.36 (m, 2H), 7.25 (m, 2H), 7.05 (d, 1H), 5.24 (s, 2H), 5.12 (m, 1H), 4.95˜4.80 (m, 2H), 3.52 (s, 3H), 3.28 (m, 1H), 2.87˜2.75 (m, 7H), 2.50 (br, 1H), 2.06 (m, 2H), 1.88 (m, 3H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.43˜7.30 (m, 5H), 7.04˜6.99 (m, 2H), 5.10 (m, 1H), 4.95˜4.80 (m, 2H), 4.13 (d, 2H), 3.71 (d, 2H), 3.41 (s, 3H), 3.28 (m, 1H), 2.88˜2.79 (m, 7H), 2.39 (br, 1H), 2.06 (m, 2H), 1.88 (m, 3H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.38 (d, 2H), 7.29 (m, 2H), 7.24 (m, 2H), 7.11 (t, 1H), 5.15 (s, 2H), 5.10 (m, 1H), 4.96˜4.79 (m, 2H), 3.45 (s, 3H), 3.28 (m, 1H), 2.88˜2.77 (m, 7H), 2.46 (br, 1H), 2.06 (m, 2H), 1.89 (m, 3H), 1.71 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.52 (m, 2H), 7.43 (m, 2H), 7.28 (d, 3H), 5.14 (m, 1H), 4.98˜4.81 (m, 2H), 3.30 (m, 1H), 2.87 (m, 7H), 2.70 (q, 2H), 2.10 (m, 2H), 1.89 (m, 4H), 1.71 (br, 1H), 1.61 (br, 1H), 1.42 (br, 1H), 1.29 (t, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.51 (d, 1H), 7.43 (m, 2H), 7.27 (m, 3H), 5.09 (m, 1H), 4.96˜4.80 (m, 2H), 3.30 (m, 1H), 2.87˜2.76 (m, 7H), 2.64 (t, 2H), 2.10 (m, 2H), 1.89 (m, 3H), 1.74 (m, 3H), 1.61 (br, 1H), 1.42 (br, 1H), 0.99 (t, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.51 (d, 2H), 7.42 (d, 2H), 7.27 (m, 3H), 5.11 (m, 1H), 4.96˜4.81 (m, 2H), 3.32 (m, 1H), 2.87˜2.78 (m, 7H), 2.66 (t, 2H), 2.10 (m, 2H), 1.89 (m, 3H), 1.72 (br, 1H), 1.67 (m, 3H), 1.43 (m, 3H), 0.98 (t, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.52 (d, 2H), 7.42 (m, 2H), 7.32 (m, 3H), 5.05 (m, 1H), 4.96˜4.81 (m, 2H), 3.30 (m, 1H), 2.97 (m, 1H), 2.87˜2.79 (m, 7H), 2.26 (br, 1H), 2.07 (m, 2H), 1.89 (m, 3H), 1.72 (br, 1H), 1.61 (br, 1H), 1.42 (br, 1H), 1.25 (d, 6H)
1H-NMR (400 MHz, CDCl3) δ 7.50 (d, 1H), 7.43 (m, 3H), 7.33 (s, 1H), 7.23 (d, 2H), 5.10 (m, 1H), 4.95˜4.81 (m, 2H), 3.30 (m, 1H), 2.87˜2.78 (m, 7H), 2.52 (d, 2H), 2.08 (m, 2H), 1.89 (m, 4H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 0.96 (d, 6H)
1H-NMR (400 MHz, CDCl3) δ 7.53 (m, 1H), 7.51 (m, 3H), 7.46 (m, 2H), 7.33 (s, 1H), 5.05 (m, 1H), 4.96˜4.81 (m, 2H), 3.30 (m, 1H), 2.88˜2.78 (m, 7H), 2.31 (br, 1H), 2.06 (m, 2H), 1.88 (m, 3H), 1.72 (br, 1H), 1.61 (br, 1H), 1.38 (br, 1H), 1.28 (s, 9H)
1H-NMR (400 MHz, CDCl3) δ 7.48˜7.41 (m, 4H), 7.31 (m, 1H), 7.15 (m, 2H), 5.14 (m, 1H), 4.94˜4.80 (m, 2H), 3.28 (m, 1H), 2.86˜2.78 (m, 7H), 2.08 (m, 2H), 1.88 (m, 4H), 1.71 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H), 1.01 (m, 2H), 0.75 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.43 (m, 4H), 7.33 (m, 2H), 7.21 (d, 1H), 5.10 (m, 1H), 4.96˜4.80 (m, 2H), 3.30 (m, 1H), 2.87˜2.75 (m, 7H), 2.74 (q, 2H), 2.09 (m, 2H), 1.89 (m, 4H), 1.71 (br, 1H), 1.0 (br, 1H), 1.42 (br, 1H), 1.30 (t, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.58 (s, 1H), 7.44 (s, 2H), 7.42 (m, 3H), 7.32 (s, 1H), 5.03 (m, 1H), 4.97˜4.81 (m, 2H), 3.30 (m, 1H), 2.89˜2.80 (m, 7H), 2.14 (m, 2H), 1.90 (m, 4H), 1.73 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.39 (s, 9H) Example 40. (S)-quinuclidin-3-yl (6-(3-isopropylphenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate
1H-NMR (400 MHz, CDCl3) δ 7.44˜7.33 (m, 6H), 7.24 (m, 1H), 5.11 (m, 1H), 4.96˜4.80 (m, 2H), 3.30 (m, 1H), 3.02 (m, 1H), 2.88˜2.75 (m, 7H), 2.55 (br, 1H), 2.14 (m, 2H), 1.89 (m, 3H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H), 1.28 (d, 6H)
1H-NMR (400 MHz, CDCl3) δ 7.40 (m, 1H), 7.32 (m, 3H), 7.23 (m, 1H), 7.18 (m, 1H), 7.05 (s, 1H), 5.15 (m, 1H), 4.97˜4.81 (m, 2H), 3.28 (m, 1H), 2.88˜2.77 (m, 7H), 2.62 (q, 2H), 2.46 (br, 1H), 2.06 (m, 2H), 1.89 (m, 3H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H), 1.13 (t, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.45 (t, 1H), 7.36 (m, 1H), 7.25 (m, 3H), 7.12 (d, 1H), 5.07 (m, 1H), 4.95˜4.80 (m, 2H), 3.29 (m, 1H), 2.87˜2.78 (m, 7H), 2.43 (br, 1H), 2.13 (m, 2H), 1.89 (m, 3H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.38 (m, 2H), 7.28 (m, 1H), 7.08 (m, 2H), 6.93 (d, 1H), 5.03 (m, 1H), 4.91˜4.80 (m, 2H), 4.31 (s, 4H), 3.28 (m, 1H), 2.22 (br, 1H), 2.06 (m, 2H), 1.87 (m, 3H), 1.71 (br, 1H), 1.61 (br, 1H), 1.42 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.42˜7.27 (m, 5H), 6.85 (d, 1H), 5.05 (m, 1H), 4.94˜4.80 (m, 2H), 4.63 (t, 2H), 3.28 (m, 3H), 2.86˜2.78 (m, 7H), 2.24 (br, 1H), 2.06 (m, 2H), 1.88 (m, 3H), 1.71 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.53 (d, 2H), 7.40 (m, 2H), 7.30 (m, 1H), 6.98 (d, 2H), 5.07 (m, 1H), 4.95˜4.79 (m, 2H), 3.90 (m, 4H), 3.31 (m, 1H), 3.23 (m, 4H), 2.86˜2.77 (m, 7H), 2.13 (m, 2H), 1.88 (m, 4H), 1.70 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.53 (d, 2H), 7.40 (m, 3H), 7.28 (m, 1H), 6.98 (d, 1H), 5.04 (m, 1H), 4.95˜4.81 (m, 1H), 3.86 (s, 3H), 3.29 (m, 1H), 2.86˜2.79 (m, 7H), 2.30 (br, 1H), 2.09 (m, 2H), 1.88 (m, 3H), 1.72 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.43 (m, 2H), 7.36 (m, 2H), 7.17 (d, 1H), 7.10 (s, 1H), 6.91 (d, 1H), 5.07 (m, 1H), 4.96˜4.81 (m, 2H), 3.88 (s, 3H), 3.31 (m, 1H), 2.87˜2.78 (m, 7H), 2.38 (br, 1H), 2.10 (m, 2H), 1.89 (m, 3H), 1.71 (br, 1H), 1.60 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.39 (m, 2H), 7.31˜7.28 (m, 3H), 7.01 (m, 2H), 5.06 (m, 1H), 4.96˜4.81 (m, 2H), 3.83 (s, 3H), 3.29 (m, 1H), 2.86˜2.79 (m, 7H), 2.30 (br, 1H), 2.07 (m, 2H), 1.88 (m, 3H), 1.72 (br, 1H), 1.62 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.45 (s, 1H), 7.48 (m, 2H), 7.38 (m, 2H), 5.13 (m, 1H), 4.97˜4.79 (m, 2H), 3.26 (m, 1H), 2.86˜2.76 (m, 7H), 2.05 (m, 2H), 1.81 (m, 4H), 1.70 (br, 1H), 1.59 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 8.54 (m, 1H), 7.68 (m, 1H), 7.47 (m, 2H), 7.37 (m, 2H), 4.99 (m, 2H), 4.80 (m, 1H), 3.29 (m, 1H), 2.88˜2.79 (m, 7H), 2.63 (s, 3H), 2.09 (m, 2H), 1.89 (m, 4H), 1.72 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 8.21 (s, 1H), 7.44 (, 2H), 7.35 (s, 1H), 7.08 (s, 1H), 6.93 (m, 1H), 5.04 (m, 1H), 4.96˜4.79 (m, 2H), 3.99 (s, 3H), 3.27 (m, 1H), 2.86˜2.76 (m, 7H), 2.06 (m, 2H), 1.89 (m, 4H), 1.70 (br, 1H), 1.58 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 9.64 (br, 1H), 8.11 (s, 1H), 7.45 (m, 2H), 7.31 (m, 1H), 7.12 (m, 2H), 6.56 (s, 1H), 5.21 (m, 1H), 4.97˜4.81 (m, 2H), 3.29 (m, 1H), 3.87˜2.79 (m, 7H), 2.06 (m, 2H), 1.90 (m, 4H), 1.71 (br, 1H), 1.62 (br, 1H), 1.42 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 9.20 (s, 1H), 8.92 (s, 2H), 7.67 (m, 1H), 7.49 (m, 1H), 7.40 (m, 1H), 5.09 (m, 1H), 4.98˜4.80 (m, 2H), 3.28 (m, 1H), 2.87˜2.77 (m, 7H), 2.06 (m, 2H), 1.91 (m, 4H), 1.70 (br, 1H), 1.59 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 9.84 (br, 1H), 8.37 (s, 1H), 7.60 (m, 1H), 7.54 (s, 2H), 7.40 (s, 1H), 7.18 (m, 1H), 6.71 (s, 1H), 5.10 (m, 1H), 5.01˜4.83 (m, 2H), 3.32 (m, 1H), 2.90˜2.84 (m, 7H), 2.14 (m, 2H), 1.93 (m, 4H), 1.73 (br, 1H), 1.62 (br, 1H), 1.43 (br, 1H)
The titled compounds of Examples 55 to 85 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (7-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate prepared in Preparation 2; and the corresponding substituted-boronic acids, respectively.
1H-NMR (400 MHz, CDCl3) δ 7.52 (d, 2H), 7.37 (d, 1H), 7.28 (m, 1H), 7.17 (d, 1H), 7.11 (m, 2H), 4.98 (m, 2H), 4.78 (m, 1H), 3.25 (m, 1H), 2.83˜2.70 (m, 7H), 2.04 (m, 2H), 1.89 (m, 3H), 1.78 (br, 1H), 1.68 (br, 1H), 1.57 (br, 1H), 1.37 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.50 (m, 3H), 7.39 (m, 3H), 7.17 (d, 1H), 4.99 (m, 2H), 4.78 (m, 1H), 3.25 (m, 1H), 2.83˜2.70 (m, 7H), 2.05 (m, 2H), 1.88 (m, 3H), 1.79 (br, 1H), 1.68 (br, 1H), 1.59 (br, 1H), 1.37 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.44 (m, 3H), 7.23 (m, 2H), 7.15 (m, 2H), 5.10 (m, 1H), 4.93 (m, 1H), 4.76 (m, 1H), 2.27 (m, 1H), 2.86˜2.72 (m, 7H), 2.38 (s, 3H), 2.11 (m, 3H), 1.99˜1.86 (m, 3H), 1.66 (br, 1H), 1.56 (br, 1H), 1.37 (br, 1H),
1H-NMR (400 MHz, CDCl3) δ 7.56 (d, 1H), 7.41 (m, 2H), 7.35 (m, 2H), 7.18 (m, 1H), 7.04 (m, 1H), 5.13 (m, 1H), 4.97 (m, 1H), 4.60 (m, 1H), 3.28 (m, 1H), 2.85˜2.75 (m, 7H), 2.24 (m, 1H), 2.08 (m, 1H), 1.89 (m, 3H), 1.81 (br, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.39 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.54 (s, 2H), 7.40˜7.28 (m, 4H), 7.20 (m, 1H), 5.13 (m, 1H), 4.97 (m, 1H), 4.78 (m, 1H), 3.28 (m, 1H), 2.85˜2.75 (m, 7H), 2.35 (br, 1H), 2.08 (m, 1H), 1.89 (m, 3H), 1.81 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.78 (m, 1H), 7.73 (m, 1H), 7.55 (m, 3H), 7.42 (m, 1H), 7.20 (d, 1H), 5.00 (m, 2H), 4.78 (m, 1H), 3.26 (m, 1H), 2.84˜2.71 (m, 7H), 2.11 (m, 4H), 1.96 (m, 1H), 1.79 (br, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.39 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.51 (m, 1H), 7.41 (m, 2H), 7.31 (m, 1H), 7.22 (m, 3H), 5.20 (m, 1H), 4.97 (m, 1H), 4.76 (m, 1H), 3.26 (m, 1H), 2.84˜2.69 (m, 7H), 2.31 (br, 1H), 2.08 (m, 1H), 1.88 (m, 3H), 1.80 (br, 1H), 1.68 (br, 1H), 1.57 (br, 1H), 1.37 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.44 (m, 2H), 7.30 (m, 4H), 7.16 (d, 1H), 5.17 (m, 1H), 4.93 (m, 1H), 4.73 (m, 1H), 3.20 (m, 1H), 2.84˜2.67 (m, 7H), 2.09 (m, 3H), 1.87 (m, 2H), 1.77 (br, 1H), 1.65 (br, 1H), 1.54 (br, 1H), 1.35 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.73 (m, 1H), 7.56 (m, 1H), 7.45 (m, 1H), 7.30 (m, 2H), 7.13 (m, 2H), 5.12 (m, 1H), 4.92 (m, 1H), 4.71 (m, 1H), 3.20 (m, 1H), 2.82˜2.68 (m, 7H), 2.09 (m, 3H), 1.87 (m, 2H), 1.77 (br, 1H), 1.64 (br, 1H), 1.53 (br, 1H), 1.33 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.50 (m, 1H), 7.34 (m, 2H), 7.26˜7.16 (m, 3H), 5.11 (m, 1H), 4.94 (m, 1H), 4.76 (m, 1H), 3.26 (m, 1H), 2.82˜2.69 (m, 7H), 2.02 (m, 3H), 1.87 (m, 2H), 1.78 (br, 1H), 1.68 (br, 1H), 1.56 (br, 1H), 1.36 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.45 (m, 1H), 7.36 (m, 2H), 7.16 (d, 1H), 6.92 (m, 2H), 5.13 (m, 1H), 4.94 (m, 1H), 4.75 (m, 1H), 3.22 (m, 1H), 2.83˜2.68 (m, 7H), 2.11 (m, 3H), 1.87 (m, 2H), 1.77 (br, 1H), 1.66 (br, 1H), 1.55 (br, 1H), 1.35 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.44 (m, 1H), 7.30˜7.17 (m, 3H), 7.01 (m, 1H), 5.12 (m, 1H), 4.93 (m, 1H), 4.75 (m, 1H), 3.22 (m, 1H), 2.83˜2.68 (m, 7H), 2.05 (m, 3H), 1.88 (m, 2H), 1.77 (br, 1H), 1.66 (br, 1H), 1.56 (br, 1H), 1.36 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.50 (d, 1H), 7.35 (m, 1H), 7.18 (d, 1H), 7.11 (m, 2H), 6.98 (m, 1H), 5.18 (m, 1H), 4.95 (m, 1H), 4.78 (m, 1H), 3.25 (m, 1H), 2.85˜2.73 (m, 7H), 2.28 (br, 1H), 2.08 (m, 1H), 1.89 (m, 3H), 1.80 (br, 1H), 1.67 (m, 1H), 1.57 (br, 1H), 1.38 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.52 (m, 1H), 7.37 (m, 1H), 7.19 (d, 1H), 7.08 (m, 2H), 6.78 (m, 1H), 5.08 (m, 1H), 4.97 (m, 1H), 4.80 (m, 1H), 3.28 (m, 1H), 2.85˜2.76 (m, 7H), 2.09 (m, 2H), 1.93 (m, 1H), 1.89 (m, 2H), 1.81 (br, 1H), 1.69 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.43 (m, 1H), 7.28 (m, 1H), 7.18 (d, 1H), 7.10 (m, 1H), 7.03 (m, 1H), 5.27 (m, 1H), 4.94 (m, 1H), 4.76 (m, 1H), 3.23 (m, 1H), 2.82˜2.66 (m, 7H), 2.07 (m, 3H), 1.88 (m, 2H), 1.81 (br, 1H), 1.67 (br, 1H), 1.56 (br, 1H), 1.37 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.63 (s, 1H), 7.48 (m, 2H), 7.38 (m, 2H), 7.18 (d, 1H), 5.14 (m, 1H), 4.94 (m, 1H), 4.76 (m, 1H), 3.22 (m, 1H), 2.83˜2.68 (m, 7H), 2.06 (m, 2H), 1.87 (m, 3H), 1.78 (br, 1H), 1.67 (m, 1H), 1.56 (br, 1H), 1.37 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.40 (m, 2H), 7.32 (m, 1H), 7.27 (m, 2H), 7.17 (m, 1H), 5.12 (m, 1H), 4.96 (m, 1H), 4.76 (m, 1H), 3.26 (m, 1H), 2.85˜2.69 (m, 7H), 2.11 (m, 3H), 1.89 (m, 2H), 1.78 (br, 1H), 1.67 (br, 1H), 1.58 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 8.65 (s, 2H), 7.62 (m, 1H), 7.50 (m, 3H), 7.25 (d, 1H), 5.02 (m, 2H), 4.81 (br, 1H), 3.30 (m, 1H), 2.87˜2.72 (m, 7H), 2.13 (m, 2H), 1.90 (m, 4H), 1.71 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 8.82 (s, 1H), 8.59 (s, 1H), 7.87 (m, 1H), 7.58 (m, 1H), 7.44 (m, 1H), 7.42 (m, 1H), 7.24 (d, 1H), 5.07 (m, 2H), 4.80 (br, 1H), 3.27 (m, 1H), 2.87˜2.78 (m, 7H), 2.09˜1.99 (m, 5H), 1.82 (br, 1H), 1.71 (br, 1H), 1.61 (br, 1H), 1.41 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.26 (m, 4H), 7.17 (s, 2H), 4.99 (m, 2H), 4.77 (m, 1H), 3.29 (m, 1H), 2.85˜2.73 (m, 7H), 2.30 (s, 3H), 2.14 (m, 4H), 1.90 (br, 1H), 1.80 (br, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.51 (m, 1H), 7.38 (d, 1H), 7.31 (m, 2H), 7.16 (d, 1H), 7.05˜6.99 (m, 2H), 5.01 (m, 1H), 4.97 (m, 1H), 4.77 (br, 1H), 3.83 (s, 3H), 3.25 (m, 1H), 2.84˜2.76 (m, 7H), 2.04 (m, 2H), 1.88 (m, 4H), 1.69 (br, 1H), 1.58 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.59 (d, 1H), 7.43 (m, 1H), 7.32 (m, 2H), 7.15 (d, 1H), 7.03˜6.97 (m, 2H), 5.00 (m, 1H), 4.97 (m, 1H), 4.76 (br, 1H), 4.07 (m, 2H), 3.26 (m, 1H), 2.85˜2.76 (m, 7H), 2.06 (m, 2H), 1.89 (m, 4H), 1.69 (br, 1H), 1.59 (br, 1H), 1.38 (t, 4H)
1H-NMR (400 MHz, CDCl3) δ 7.57 (m, 1H), 7.50˜7.48 (m, 1H), 7.42 (m, 1H), 7.18 (m, 2H), 7.14 (m, 1H), 6.88 (d, 1H), 4.99 (m, 2H), 4.79 (m, 1H), 3.83 (s, 3H), 3.28 (m, 1H), 2.85˜2.78 (m, 7H), 2.06 (m, 2H), 1.89 (m, 3H), 1.82 (br, 1H), 1.59 (br, 1H), 1.71 (br, 1H), 1.48 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.60 (m, 1H), 7.41 (d, 1H), 7.31 (m, 2H), 7.13 (d, 1H), 6.99 (t, 1H), 4.99 (m, 1H), 4.93 (m, 1H), 4.77 (br, 1H), 4.54 (m, 1H), 3.28 (m, 1H), 2.84˜2.75 (m, 7H), 2.13 (m, 2H), 2.06 (m, 3H), 1.89 (m, 1H), 1.82 (br, 1H), 1.70 (br, 1H), 1.38 (br, 1H), 1.31 (d, 6H)
1H-NMR (400 MHz, CDCl3) δ 7.67 (m, 1H), 7.50 (m, 3H), 7.40 (m, 1H), 7.17 (m, 1H), 7.01 (m, 1H), 5.02 (m, 1H), 4.97˜4.78 (m, 2H), 4.18 (s, 2H), 3.79 (s, 2H), 3.48 (s, 3H), 3.29 (m, 1H), 2.84˜2.76 (m, 7H), 2.05 (m, 3H), 1.88 (m, 3H), 1.70 (br, 1H), 1.59 (br, 1H), 1.38 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.52 (m, 3H), 7.41 (m, 1H), 7.17 (m, 1H), 6.99 (m, 2H), 5.04 (m, 1H), 4.97 (m, 1H), 4.79 (m, 1H), 3.86 (s, 3H), 3.30 (m, 1H), 2.88˜2.74 (m, 7H), 2.13 (m, 3H), 1.92 (m, 3H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.50 (m, 3H), 7.40 (d, 1H), 7.16 (m, 1H), 6.97 (m, 2H), 5.04 (m, 1H), 4.97 (m, 1H), 4.80 (m, 1H), 4.10 (m, 2H), 3.30 (m, 1H), 2.88˜2.74 (m, 7H), 2.06 (m, 2H), 1.98 (m, 4H), 1.70 (br, 1H), 1.60 (br, 1H), 1.40 (br, 1H), 1.39 (t, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.53 (m, 3H), 7.41 (d, 1H), 7.17 (m, 1H), 6.98 (m, 2H), 5.01 (m, 1H), 4.97 (m, 1H), 4.79 (m, 1H), 3.97 (m, 2H), 3.28 (m, 1H), 2.87˜2.76 (m, 7H), 2.06 (m, 2H), 1.84 (m, 6H), 1.69 (br, 1H), 1.61 (br, 1H), 1.40 (br, 1H), 1.08 (t, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.52 (m, 3H), 7.39 (d, 1H), 7.16 (d, 1H), 6.97 (m, 2H), 5.04 (m, 1H), 4.97 (m, 1H), 4.79 (m, 1H), 4.59 (m, 1H), 3.27 (m, 1H), 2.84˜2.71 (m, 7H), 2.05 (m, 2H), 1.93˜1.82 (m, 4H), 1.70 (br, 1H), 1.60 (br, 1H), 1.38 (br, 1H), 1.17 (d, 6H)
1H-NMR (400 MHz, CDCl3) δ 7.50 (m, 1H), 7.35 (m, 1H), 7.16 (d, 1H), 7.05 (m, 2H), 6.89 (m, 1H), 6.01 (s, 2H), 5.02 (m, 1H), 4.96 (m, 1H), 4.78 (m, 1H), 3.31 (m, 1H), 2.87˜2.72 (m, 7H), 2.06 (m, 2H), 1.88 (m, 4H), 1.70 (br, 1H), 1.60 (br, 1H), 1.28 (br, 1H)
1H-NMR (400 MHz, CDCl3) δ 7.57˜7.38 (m, 5H), 7.18 (m, 2H), 5.01 (m, 2H), 4.78 (m, 1H), 3.29 (m, 1H), 2.86˜2.76 (m, 7H), 2.43 (s, 3H), 2.08 (m, 2H), 1.89 (m, 4H), 1.62 (br, 1H), 1.59 (br, 1H), 1.38 (br, 1H)
The titled compounds of Examples 86 to 150 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (6-bromo-2,2-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate prepared in Preparation 3; and the corresponding substituted-boronic acids, respectively.
1H-NMR (400 MHz, CDCl3) δ 7.53 (m, 3H), 7.36 (m, 2H), 7.13 (t, 2H), 4.91 (m, 2H), 4.65 (m, 1H), 3.37 (m, 1H), 3.05˜2.85 (m, 7H), 2.29 (m, 1H), 1.96 (m, 1H), 1.83 (m, 1H), 1.72 (m, 3H), 1.36 (m, 1H), 1.17 (m, 3H), 1.00 (s, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.50 (m, 2H), 7.41 (m, 2H), 7.31 (m, 3H), 4.90 (m, 2H), 4.67 (m, 1H), 3.44 (m, 1H), 3.13˜3.88 (m, 7H), 2.20 (m, 1H), 2.00 (m, 1H), 1.87 (m, 1H), 1.77 (m, 1H), 1.66 (m, 3H), 1.08 (m, 3H), 1.00 (s, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.69 (s, 4H), 7.48 (m, 1H), 7.38 (m, 2H), 4.94˜4.87 (m, 2H), 4.68 (m, 1H), 3.40 (m, 1H), 3.11˜2.90 (m, 7H), 2.26 (m, 1H), 1.85 (m, 1H), 1.73 (m, 1H), 1.58 (m, 3H), 1.40 (m, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.68 (m, 1H), 7.58 (m, 2H), 7.50 (m, 1H), 7.39 (m, 1H), 7.30 (m, 2H), 4.86 (m, 2H), 4.68 (m, 1H), 3.32 (m, 1H), 3.00˜2.84 (m, 7H), 2.31 (br, 1H), 2.15 (m, 1H), 1.91 (m, 1H), 1.73 (br, 1H), 1.66 (m, 2H), 1.50 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.68 (m, 2H), 7.57 (m, 1H), 7.49 (m, 1H), 7.42 (m, 3H), 7.05 (m, 1H), 4.86 (m, 2H), 4.68 (m, 1H), 3.37 (m, 1H), 3.00˜2.88 (m, 7H), 2.16 (m, 2H), 1.95 (br, 1H), 1.77 (br, 1H), 1.64 (m, 2H), 1.52 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.55 (s, 1H), 7.45 (m, 1H), 7.31 (m, 5H), 4.85 (m, 2H), 4.68 (m, 1H), 3.31 (m, 1H), 2.96˜2.83 (m, 7H), 2.33 (m, 1H), 2.26 (m, 1H), 1.92 (br, 1H), 1.73 (m, 2H), 1.68 (br, 1H), 1.51 (br, 1H), 1.08 (m, 3H), 0.98 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 7.71 (m, 1H), 7.60 (m, 1H), 7.48˜7.35 (m, 4H), 4.84 (m, 2H), 4.68 (m, 1H), 3.37 (m, 1H), 2.99˜2.83 (m, 7H), 2.20 (m, 2H), 2.04 (br, 1H), 1.71 (m, 3H), 1.52 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 2H), 7.65 (m, 2H), 7.43 (m, 2H), 7.20 (m, 1H), 4.85 (m, 2H), 4.68 (m, 1H), 3.40 (m, 1H), 3.06˜2.61 (m, 7H), 2.22 (m, 1H), 2.10 (s, 1H), 1.96 (m, 1H), 1.82 (br, 1H), 1.73 (m, 2H), 1.58 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.69 (m, 1H), 7.40 (m, 1H), 7.35 (m, 3H), 7.21 (m, 1H), 7.15 (m, 1H), 4.89 (m, 2H), 4.68 (m, 1H), 3.38 (m, 1H), 3.05˜2.71 (m, 7H), 2.22 (br, 1H), 2.10 (s, 1H), 1.96 (m, 1H), 1.80 (br, 1H), 1.71 (m, 2H), 1.55 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.48 (d, 1H), 7.32 (m, 5H), 7.19 (s, 1H), 4.87 (m, 2H), 4.67 (m, 1H), 3.37 (m, 1H), 2.99˜2.86 (m, 7H), 2.38 (m, 2H), 2.34 (m, 1H), 1.93 (m, 1H), 1.76 (m, 2H), 1.52 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.74 (m, 1H), 7.55 (m, 1H), 7.48 (m, 1H), 7.33 (m, 2H), 7.15 (m, 1H), 7.07 (s, 1H), 4.92 (m, 2H), 4.68 (m, 1H), 3.40 (m, 1H), 3.08˜2.62 (m, 7H), 2.26 (m, 1H), 2.10 (s, 1H), 1.99 (m, 1H), 1.82 (m, 1H), 1.73 (m, 2H), 1.58 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 1H), 7.57 (m, 1H), 7.49 (m, 1H), 7.42 (m, 1H), 7.37 (m, 2H), 7.21 (s, 1H), 4.89 (m, 2H), 4.68 (m, 1H), 3.33 (m, 1H), 2.99˜2.86 (m, 7H), 2.31 (m, 1H), 2.18 (m, 1H), 1.99 (m, 1H), 1.75 (m, 3H), 1.52 (m, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.69 (m, 1H), 7.49 (m, 3H), 7.35 (s, 1H), 7.24 (m, 2H), 5.39 (m, 2H), 4.67 (m, 1H), 3.38 (m, 1H), 3.00˜2.87 (m, 7H), 2.41 (s, 3H), 2.04 (m, 3H), 1.96 (br, 1H), 1.73 (br, 2H), 1.50 (br, 1H), 1.08 (m, 3H), 0.97 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.57 (m, 2H), 7.39 (m, 2H), 7.29 (m, 1H), 7.20 (d, 2H), 6.75˜6.38 (t, 1H), 4.88 (m, 2H), 4.66 (m, 1H), 3.37 (m, 1H), 2.98 (m, 7H), 2.24 (br, 1H), 1.95 (br, 1H), 1.76 (br, 1H), 1.72 (m, 3H), 1.50 (m, 1H), 1.07 (m, 3H), 1.00 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 1H), 7.50 (m, 1H), 7.39 (m, 3H), 7.20 (m, 1H), 4.85 (m, 2H), 4.67 (m, 1H), 3.36 (m, 1H), 3.00˜2.84 (m, 7H), 2.33 (br, 1H), 2.17 (m, 1H), 1.90 (m, 1H), 1.77 (m, 2H), 1.70 (br, 1H), 1.51 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 1H), 7.50 (m, 1H), 7.38 (m, 2H), 6.94 (m, 2H), 4.85 (m, 2H), 4.68 (m, 1H), 3.37 (m, 1H), 3.02˜2.78 (m, 7H), 2.48 (br, 1H), 2.18 (m, 1H), 2.10 (s, 1H), 1.92 (br, 1H), 1.77 (m, 2H), 1.52 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.70 (m, 1H), 7.66 (m, 1H), 7.49 (m, 1H), 7.35 (d, 1H), 7.15 (m, 2H), 4.88 (m, 2H), 4.68 (m, 1H), 3.33 (m, 1H), 3.01˜2.81 (m, 7H), 2.59 (br, 1H), 2.25 (br, 1H), 1.82 (br, 1H), 1.76 (m, 3H), 1.50 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.69˜7.49 (m, 1H), 7.35 (m, 2H), 7.13 (m, 2H), 7.01 (m, 1H), 4.90 (m, 2H), 4.68 (m, 1H), 3.29 (m, 1H), 3.04˜2.81 (m, 7H), 2.22 (m, 1H), 2.15 (m, 1H), 1.99 (m, 1H), 1.81 (br, 1H), 1.72 (m, 2H), 1.53 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.68˜7.49 (m, 1H), 7.39 (m, 2H), 7.09 (m, 2H), 6.79 (m, 1H), 4.94 (m, 2H), 4.67 (m, 1H), 3.43 (m, 1H), 3.02˜2.88 (m, 7H), 2.28 (m, 1H), 2.16 (m, 1H), 1.99 (br, 1H), 1.86 (br, 1H), 1.72 (m, 2H), 1.50 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 2H), 7.57 (m, 1H), 7.50 (m, 2H), 7.25 (m, 1H), 4.89 (m, 2H), 4.66 (m, 1H), 3.33 (m, 1H), 3.02˜2.86 (m, 7H), 2.37 (br, 2H), 2.10 (br, 1H), 1.92 (br, 1H), 1.77 (m, 2H), 1.50 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 2H), 7.55 (m, 1H), 7.50 (m, 2H), 7.38 (m, 1H), 4.86 (m, 2H), 4.68 (m, 1H), 3.39 (m, 1H), 3.04˜2.88 (m, 7H), 2.26 (m, 2H), 2.04 (br, 1H), 1.99 (br, 1H), 1.78 (m, 2H), 1.53 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 1H), 7.56 (m, 1H), 7.50 (m, 2H), 7.34 (m, 2H), 4.85 (m, 2H), 4.68 (m, 1H), 3.31 (m, 1H), 2.98˜2.86 (m, 7H), 2.14 (m, 2H), 1.94 (br, 1H), 1.73 (m, 2H), 1.65 (m, 1H), 1.51 (m, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.69 (m, 1H), 7.55 (m, 1H), 7.38 (m, 1H), 7.26 (m, 1H), 7.02 (m, 1H), 4.86 (m, 2H), 4.67 (m, 1H), 3.30 (m, 1H), 2.95˜2.87 (m, 7H), 2.51 (br, 2H), 2.08 (br, 1H), 1.73 (br, 1H), 1.64 (m, 2H), 1.49 (br, 1H), 1.06 (m, 3H), 0.98 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.68 (m, 1H), 7.54˜7.48 (m, 1H), 7.32 (m, 1H), 7.24 (m, 1H), 7.12 (m, 1H), 4.91 (m, 2H), 4.67 (m, 1H), 3.44 (m, 1H), 3.07 (m, 7H), 2.27 (br, 2H), 2.10 (br, 1H), 1.99 (br, 1H), 1.73 (m, 2H), 1.63 (br, 1H), 1.08 (m, 3H), 0.98 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.29˜7.24 (m, 2H), 7.18 (d, 2H), 7.11 (m, 1H), 6.98 (d, 2H), 4.85 (m, 1H), 4.80 (br, 1H), 4.66 (m, 1H), 4.17 (m, 2H), 3.79 (m, 2H), 3.48 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.59 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (d, 3H), 0.96 (d, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.33˜7.23 (m, 3H), 7.11 (m, 1H), 6.91 (d, 1H), 6.85 (m, 2H), 4.85 (m, 1H), 4.80 (br, 1H), 4.66 (m, 1H), 4.15 (m, 2H), 3.78 (m, 2H), 3.47 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.59 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (d, 3H), 0.96 (d, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.32˜7.21 (m, 3H), 7.10 (m, 1H), 7.07 (m, 2H), 6.96 (d, 1H), 4.88 (m, 1H), 4.79 (br, 1H), 4.66 (m, 1H), 4.12˜3.99 (m, 2H), 3.53 (m, 2H), 3.25 (m, 1H), 3.22 (m, 3H), 2.88˜2.76 (m, 5H), 2.39 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (d, 3H), 0.96 (d, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.31 (m, 2H), 7.19 (d, 2H), 7.09 (m, 3H), 5.23 (s, 2H), 4.88 (m, 1H), 4.79 (br, 1H), 4.66 (m, 1H), 3.31 (s, 3H), 3.25 (m, 1H), 3.22 (m, 3H), 2.88˜2.76 (m, 5H), 2.39 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (d, 3H), 0.96 (d, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.33˜7.23 (m, 3H), 7.11 (m, 1H), 6.91 (d, 1H), 6.85 (m, 2H), 5.20 (s, 2H), 4.88 (m, 1H), 4.79 (br, 1H), 4.66 (m, 1H), 3.30 (s, 3H), 3.25 (m, 1H), 3.22 (m, 3H), 2.88˜2.76 (m, 5H), 2.39 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (d, 3H), 0.96 (d, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.32 (m, 1H), 7.31˜7.13 (m, 3H), 7.08 (m, 3H), 5.05 (s, 2H), 4.88 (m, 1H), 4.79 (br, 1H), 4.66 (m, 1H), 3.34˜3.31 (m, 3H), 3.29 (m, 1H), 3.22 (m, 3H), 2.88˜2.76 (m, 5H), 2.39 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (d, 3H), 0.96 (d, 3H)
1H-NMR (400 MHz, CDCl3) δ 8.20 (d, 1H), 7.37 (m, 1H), 7.27 (m, 1H), 7.06 (m, 1H), 6.79 (m, 1H), 6.66 (s, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 3.98 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.04 (m, 3H), 0.96 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 8.54 (d, 1H), 7.36 (m, 1H), 7.27 (s, 2H), 7.04 (s, 1H), 7.02 (d, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.57 (s, 3H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (m, 3H), 0.97 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 8.26 (d, 1H), 7.38 (m, 1H), 7.27 (m, 2H), 7.08 (m, 1H), 7.07 (m, 1H), 6.84 (s, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (m, 3H), 0.96 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 8.78 (d, 1H), 7.62 (s, 1H), 7.44 (m, 2H), 7.31 (m, 1H), 7.09 (m, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.07 (m, 3H), 0.96 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.32 (m, 2H), 7.20 (m, 2H), 7.11 (m, 1H), 6.95 (d, 2H), 4.87 (m, 2H), 4.65 (m, 1H), 3.86 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (m, 3H), 0.96 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 2H), 7.27 (m, 2H), 7.13 (m, 1H), 6.86 (m, 2H), 6.81 (s, 1H), 4.87 (m, 2H), 4.65 (m, 1H), 3.84 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (m, 3H), 0.97 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.34˜7.12 (m, 3H), 7.09 (m, 1H), 6.87 (d, 1H), 6.84 (d, 1H), 6.81 (s, 1H), 4.87 (m, 2H), 4.65 (m, 1H), 4.01 (m, 2H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.45 (t, 3H), 1.05 (m, 3H), 0.97 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.25 (m, 1H), 7.08 (m, 1H), 7.01 (m, 2H), 6.87 (d, 1H), 4.91 (m, 1H), 4.87 (m, 1H), 4.65 (m, 1H), 3.87 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.03 (m, 3H), 0.97 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.38 (d, 1H), 7.28 (m, 1H), 7.25 (m, 1H), 7.10 (m, 1H), 6.79 (m, 2H), 4.91 (m, 1H), 4.85 (m, 1H), 4.66 (m, 1H), 3.86 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.03 (m, 3H), 0.97 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.37 (m, 2H), 7.26 (m, 1H), 7.03 (m, 1H), 6.86 (m, 1H), 6.74 (m, 1H), 4.91 (m, 1H), 4.85 (m, 1H), 4.66 (m, 1H), 3.81 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.03 (m, 3H), 0.97 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.34˜7.22 (m, 2H), 7.04 (m, 1H), 7.00 (m, 3H), 4.91 (m, 1H), 4.85 (m, 1H), 4.66 (m, 1H), 3.94 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.56 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.03 (m, 3H), 0.97 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.26 (m, 2H), 7.18 (d, 1H), 7.10 (m, 3H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.67 (m, 2H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.28 (t, 3H), 1.04 (m, 3H), 0.96 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.39˜7.27 (m, 5H), 7.14 (m, 1H), 7.10 (d, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.35 (s, 9H), 1.06 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.35 (m, 2H), 7.26 (m, 2H), 7.20 (m, 1H), 7.11 (s, 1H), 7.08 (m, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 3.25 (m, 1H), 2.95 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.28 (d, 6H), 1.06 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.51 (m, 2H), 7.42 (m, 2H), 7.30 (m, 1H), 7.25 (m, 1H), 7.10 (m, 2H), 6.84˜6.55 (t, 1H), 4.85 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.06 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.30 (m, 4H), 7.15 (m, 1H), 6.73 (m 1H), 6.63 (m, 2H), 4.87 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 3.25 (m, 1H), 2.98 (s, 6H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.06 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.30 (m, 4H), 7.12 (m, 1H), 6.87 (m 1H), 6.79 (m, 2H), 4.87 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 4.57 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.36 (d, 6H), 1.06 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.30 (m, 1H), 7.25 (m, 1H), 7.11 (m, 2H), 6.95 (d, 1H), 6.74 (m, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 3.92 (s, 3H), 3.50 (m, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.06 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.29 (m, 1H), 7.25 (m, 1H), 7.07 (m, 1H), 7.01 (m, 1H), 6.55 (m, 2H), 4.87 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 3.86 (s, 3H), 3.73 (m, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.06 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.27 (m, 1H), 7.25 (m, 1H), 7.08 (m, 1H), 6.89 (s, 2H), 6.70 (d, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 3.79 (s, 3H), 3.69 (m, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.06 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.31 (m, 3H), 7.03 (m, 1H), 6.65 (d, 2H), 4.87 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 3.72 (s, 6H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.03 (m, 3H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.31 (m, 2H), 7.11 (m, 1H), 6.91 (d, 1H), 6.79 (m, 2H), 4.87 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.03 (m, 3H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 2H), 7.11 (m, 1H), 6.46 (s, 1H), 6.41 (s, 2H), 4.87 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 3.82 (s, 6H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 2H), 1.40 (br, 1H), 1.03 (m, 3H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.33˜7.20 (m, 3H), 7.14 (d, 1H), 7.08 (m, 1H), 6.97 (d, 1H), 4.89 (m, 1H), 4.77 (m, 1H), 4.67 (m, 1H), 3.94 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.57 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.61 (br, 3H), 1.42 (br, 1H), 1.03 (m, 3H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.33˜7.20 (m, 3H), 7.11 (d, 2H), 6.95 (d, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 4.13 (m, 2H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.93 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.61 (br, 3H), 1.48 (t, 3H), 1.42 (br, 1H), 1.03 (m, 3H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.31˜7.21 (m, 3H), 7.08 (m, 2H), 6.95 (d, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 4.02 (m, 2H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.93 (br, 1H), 1.87 (m, 2H), 1.85 (br, 1H), 1.70 (br, 1H), 1.61 (br, 3H), 1.42 (br, 1H), 1.10 (t, 3H), 1.03 (m, 3H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.33˜7.22 (m, 2H), 7.08 (m, 1H), 7.00 (m, 2H), 6.97 (m, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 4.57 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.61 (br, 3H), 1.40 (d, 6H), 1.03 (m, 3H), 0.94 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.31˜7.22 (m, 3H), 7.08 (m, 2H), 6.97 (d, 1H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 4.06 (m, 2H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (m, 3H), 1.70 (br, 1H), 1.59 (m, 5H), 1.40 (br, 1H), 1.05 (m, 3H), 1.03 (t, 3H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.33˜7.22 (m, 2H), 7.08 (m, 1H), 6.99 (m, 3H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 4.17 (m, 2H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.48 (t, 3H), 1.40 (br, 1H), 1.04 (m, 3H), 0.96 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.33˜7.22 (m, 2H), 7.08 (m, 1H), 6.99 (m, 3H), 4.87 (m, 1H), 4.77 (m, 1H), 4.65 (m, 1H), 4.05 (m, 2H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.10 (br, 1H), 1.88 (m, 2H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.08 (t, 3H), 1.04 (m, 3H), 0.96 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.28˜7.20 (m, 2H), 7.07 (m, 1H), 6.89 (s, 2H), 4.86 (m, 1H), 4.78 (m, 1H), 4.65 (m, 1H), 3.78 (m, 2H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.31 (s, 6H), 2.10 (br, 1H), 1.88 (m, 2H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.12 (t, 3H), 1.04 (m, 3H), 0.96 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.28˜7.20 (m, 2H), 7.08 (m, 1H), 6.89 (s, 2H), 4.86 (m, 1H), 4.78 (m, 1H), 4.65 (m, 1H), 3.80 (m, 2H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.58 (m, 2H), 2.31 (s, 6H), 2.10 (br, 1H), 1.85 (m, 3H), 1.70 (br, 1H), 1.59 (m, 5H), 1.40 (br, 1H), 1.05 (m, 3H), 1.01 (t, 3H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.35 (m, 1H), 7.25 (m, 1H), 7.08 (m, 2H), 6.77 (d, 1H), 6.68 (d, 1H), 4.86 (m, 1H), 4.80 (m, 1H), 4.68 (m, 1H), 3.84 (s, 3H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.55 (br, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (br, 1H), 1.05 (m, 3H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.32˜7.21 (m, 3H), 7.07 (m, 2H), 6.97 (d, 1H), 4.89 (m, 1H), 4.80 (m, 1H), 4.68 (m, 1H), 4.59 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.55 (m, 2H), 2.10 (br, 1H), 1.85 (br, 1H), 1.70 (br, 1H), 1.59 (m, 3H), 1.40 (d, 7H), 1.03 (m, 3H), 0.96 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.62 (d, 1H), 7.37 (m, 1H), 7.26 (m, 1H), 7.09 (m, 1H), 6.93 (m, 1H), 4.80 (m, 1H), 4.70 (m, 1H), 4.67 (m, 1H), 3.25 (m, 1H), 2.88˜2.76 (m, 5H), 2.44 (m, 2H), 2.10 (br, 1H), 1.95 (m, 3H), 1.85 (br, 1H), 1.70 (br, 1H), 1.61 (br, 1H), 1.42 (br, 1H), 1.01 (m, 3H), 0.89 (m, 3H)
The titled compounds of Examples 151 to 170 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (7-bromo-2,2-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate prepared in Preparation 4; and the corresponding substituted-boronic acids, respectively.
1H-NMR (400 MHz, CDCl3) δ 7.53 (m, 2H), 7.46 (m, 1H), 7.38 (m, 1H), 7.18 (m, 1H), 7.11 (m, 2H), 4.83 (m, 2H), 4.68 (m, 1H), 3.30 (m, 1H), 2.99˜2.81 (m, 7H), 2.14 (m, 1H), 1.99 (m, 1H), 1.89 (m, 1H), 1.74 (m, 2H), 1.64 (m, 1H), 1.37 (m, 1H), 1.12 (m, 3H), 1.08 (s, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.56 (m, 1H), 7.48 (m, 3H), 7.42 (m, 2H), 7.20 (d, 1H), 4.84 (m, 2H), 4.66 (m, 1H), 3.32 (m, 1H), 2.98˜2.85 (m, 7H), 2.12 (m, 2H), 1.86 (m, 1H), 1.72 (m, 2H), 1.64 (m, 1H), 1.51 (m, 1H), 1.08 (m, 3H), 0.99 (s, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.66 (m, 4H), 7.51˜7.42 (m, 2H), 7.23 (m, 1H), 4.85˜4.81 (m, 2H), 4.68 (m, 1H), 3.29 (m, 1H), 2.88˜2.75 (m, 7H), 2.26 (m, 1H), 2.09 (m, 1H), 1.84 (m, 1H), 1.73 (m, 2H), 1.61 (m, 1H), 1.43 (m, 1H), 1.08 (m, 3H), 0.99 (s, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 1H), 7.55 (m, 2H), 7.48 (m, 2H), 7.39 (m, 1H), 7.19 (m, 1H), 4.84 (m, 2H), 4.68 (m, 1H), 3.30 (m, 1H), 2.85 (m, 7H), 2.23˜2.14 (m, 2H), 1.85 (m, 1H), 1.72 (m, 2H), 1.63 (m, 1H), 1.44 (m, 1H), 1.08 (m, 3H), 0.99 (s, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 1H), 7.56 (m, 1H), 7.45 (m, 2H), 7.39 (m, 1H), 7.26 (m, 1H), 7.03 (m, 1H), 4.87 (m, 2H), 4.69 (m, 1H), 3.31 (m, 1H), 2.87˜2.73 (m, 7H), 2.09 (m, 2H), 1.84 (m, 1H), 1.72 (m, 2H), 1.61 (br, 1H), 1.43 (br, 1H), 1.09 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.53˜7.31 (m, 6H), 7.20 (m, 1H), 4.83 (m, 2H), 4.68 (m, 1H), 3.33 (m, 1H), 2.88˜2.81 (m, 7H), 2.09 (m, 2H), 1.86 (br, 1H), 1.72 (m, 2H), 1.62 (br, 1H), 1.46 (br, 1H), 1.09 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.80 (m, 2H), 7.56 (m, 2H), 7.51 (m, 1H), 7.43 (m, 1H), 7.22 (m, 1H), 4.87 (m, 2H), 4.69 (m, 1H), 3.30 (m, 1H), 2.88˜2.77 (m, 7H), 2.13 (m, 2H), 1.86 (m, 1H), 1.73 (m, 2H), 1.62 (br, 1H), 1.42 (br, 1H), 1.09 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.48 (m, 3H), 7.40 (m, 2H), 7.21 (m, 2H), 4.86 (m, 2H), 4.71 (m, 1H), 3.32 (m, 1H), 2.92˜2.86 (m, 7H), 2.17 (br, 1H), 2.10 (m, 2H), 1.90 (m, 1H), 1.70 (br, 1H), 1.66 (br, 1H), 1.47 (br, 1H), 1.09 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 1H), 7.47 (m, 3H), 7.21 (m, 2H), 7.16 (m, 1H), 4.86 (m, 2H), 4.69 (m, 1H), 3.30 (m, 1H), 2.89˜2.81 (m, 7H), 2.13 (m, 2H), 1.86 (br, 1H), 1.72 (m, 2H), 1.62 (br, 1H), 1.45 (br, 1H), 1.09 (m, 3H), 1.00 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 1H), 7.55 (m, 2H), 7.31 (m, 3H), 7.17 (m, 1H), 4.85 (m, 2H), 4.69 (m, 1H), 3.30 (m, 1H), 2.87˜2.77 (m, 7H), 2.19 (m, 2H), 1.86 (m, 1H), 1.72 (m, 2H), 1.60 (br, 1H), 1.41 (br, 1H), 1.09 (m, 3H), 1.00 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.74 (m, 1H), 7.56 (m, 1H), 7.48 (m, 1H), 7.33 (m, 1H), 7.26 (m, 1H), 7.15 (s, 2H), 4.82 (m, 2H), 4.67 (m, 1H), 3.29 (m, 1H), 2.87˜2.72 (m, 7H), 2.20 (m, 2H), 1.86 (br, 1H), 1.72 (m, 2H), 1.59 (br, 1H), 1.43 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.69 (m, 2H), 7.48 (m, 4H), 7.18 (m, 1H), 4.81 (m, 2H), 4.68 (m, 1H), 3.30 (m, 1H), 2.87˜2.77 (m, 7H), 2.10 (m, 2H), 1.86 (br, 1H), 1.73 (m, 2H), 1.61 (br, 1H), 1.45 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.93 (m, 1H), 7.45 (m, 2H), 7.21 (m, 4H), 4.84 (m, 2H), 4.68 (m, 1H), 3.12 (m, 1H), 2.98˜2.84 (m, 7H), 2.40 (s, 3H), 2.16 (m, 1H), 2.13 (m, 1H), 1.93 (br, 1H), 1.72 (m, 2H), 1.63 (br, 1H), 1.47 (br, 1H), 1.07 (m, 3H), 0.98 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.71 (m, 2H), 7.55 (m, 1H), 7.37 (m, 1H), 7.20 (s, 3H), 6.74˜6.38 (t, 1H), 4.84 (m, 2H), 4.69 (m, 1H), 3.21 (m, 1H), 2.91˜2.81 (m, 7H), 2.22 (m, 2H), 1.89 (br, 1H), 1.72 (m, 2H), 1.64 (br, 1H), 1.47 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.50 (m, 3H), 7.40 (m, 1H), 7.17 (m, 1H), 7.09 (m, 1H), 7.01 (m, 1H), 4.90˜4.80 (m, 2H), 4.67 (m, 1H), 4.18 (s, 2H), 3.79 (s, 2H), 3.48 (s, 3H), 3.25 (m, 1H), 2.91˜2.76 (m, 7H), 2.10 (m, 2H), 1.88 (br, 1H), 1.71 (br, 2H), 1.60 (br, 1H), 1.40 (br, 1H), 1.08 (m, 3H), 0.98 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.46 (m, 1H), 7.41 (m, 1H), 7.34 (m, 1H), 7.18 (m, 3H), 6.90 (d, 1H), 4.90˜4.80 (m, 2H), 4.67 (m, 1H), 4.18 (s, 2H), 3.79 (m, 2H), 3.48 (m, 3H), 3.27 (m, 1H), 2.86˜2.72 (m, 7H), 2.10 (m, 2H), 1.88 (br, 1H), 1.73 (br, 2H), 1.60 (br, 1H), 1.40 (br, 1H), 1.07 (m, 3H), 0.98 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.48 (d, 1H), 7.41 (d, 1H), 7.28 (m, 2H), 7.12 (m, 1H), 7.04 (m, 2H), 4.98 (d, 1H), 4.76 (br, 1H), 4.67 (d, 1H), 4.12 (m, 2H), 3.70 (m, 2H), 3.37 (s, 3H), 3.26 (m, 1H), 2.85˜2.76 (m, 7H), 2.10 (m, 2H), 1.88 (br, 1H), 1.73 (br, 2H), 1.60 (br, 1H), 1.40 (br, 1H), 1.07 (m, 3H), 0.98 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.48 (m, 3H), 7.37 (d, 1H), 7.16 (d, 1H), 7.09 (m, 2H), 5.22 (s, 2H), 4.80 (m, 2H), 4.67 (d, 1H), 3.51 (s, 3H), 3.27 (m, 1H), 2.87˜2.72 (m, 7H), 2.22 (m, 2H), 1.89 (br, 1H), 1.72 (m, 2H), 1.64 (br, 1H), 1.47 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.49 (m, 1H), 7.39 (d, 1H), 7.33 (m, 1H), 7.23˜7.16 (m, 3H), 7.02 (d, 1H), 5.23 (s, 2H), 4.81 (m, 2H), 4.67 (d, 1H), 3.51 (s, 3H), 3.27 (m, 1H), 2.87˜2.72 (m, 7H), 2.22 (m, 2H), 1.89 (br, 1H), 1.72 (m, 2H), 1.64 (br, 1H), 1.47 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.55 (m, 1H), 7.49 (m, 1H), 7.37 (m, 1H), 7.26 (m, 2H), 7.20 (m, 1H), 7.07 (m, 1H), 5.13 (m, 2H), 4.84 (m, 2H), 4.69 (m, 1H), 3.43 (s, 3H), 3.25 (m, 1H), 2.91˜2.74 (m, 7H), 2.22 (m, 2H), 1.89 (br, 1H), 1.72 (m, 2H), 1.64 (br, 1H), 1.47 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
The titled compounds of Examples 171 to 185 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (7′-bromo-3′,4′-dihydro-1′H-spiro[cyclopropane-1,2′-naphthalen]-1′-yl)carbamate prepared in Preparation 6; and the corresponding substituted-boronic acids, respectively.
1H-NMR (400 MHz, CDCl3) δ 7.53 (m, 3H), 7.40 (d, 1H), 7.23 (d, 1H), 7.13 (m, 2H), 5.15 (br, 1H), 4.76 (br, 1H), 4.32 (m, 1H), 3.26 (m, 1H), 2.94˜2.72 (m, 7H), 2.13 (m, 3H), 1.79 (br, 1H), 1.67 (br, 1H), 1.58 (br, 1H), 1.38 (br, 1H), 0.92 (m, 1H), 0.58 (m, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.49 (m, 2H), 7.41 (m, 4H), 7.24 (d, 1H), 5.17 (br, 1H), 4.76 (m, 1H), 4.33 (m, 1H), 3.26 (m, 1H), 2.91˜2.73 (m, 7H), 2.09 (m, 3H), 1.79 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.38 (br, 1H), 0.92 (m, 1H), 0.58 (m, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.69 (s, 4H), 7.56 (d, 1H), 7.46 (d, 1H), 7.25 (m, 1H), 5.18 (br, 1H), 4.77 (m, 1H), 4.34 (m, 1H), 3.27 (m, 1H), 2.92˜2.73 (m, 7H), 2.14 (m, 3H), 1.79 (br, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.38 (br, 1H), 0.92 (m, 1H), 0.58 (m, 1H), 0.50 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.58 (m, 2H), 7.50 (m, 1H), 7.43 (d, 1H), 7.28 (m, 3H), 5.17 (br, 1H), 4.76 (m, 1H), 4.33 (m, 1H), 3.29 (m, 1H), 2.90˜2.78 (m, 7H), 2.13 (m, 3H), 1.79 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 0.92 (m, 1H), 0.58 (m, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.53 (d, 1H), 7.44˜7.35 (m, 3H), 7.24 (t, 2H), 7.04 (t, 1H), 5.20 (m, 1H), 4.77 (m, 1H), 4.34 (m, 1H), 3.27 (m, 1H), 2.94˜2.73 (m, 7H), 2.06 (m, 3H), 1.82 (br, 1H), 1.70˜1.67 (br, 1H), 1.58 (br, 1H), 1.41 (br, 1H), 0.92 (m, 1H), 0.58 (br, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.69 (t, 1H), 7.55˜7.41 (m, 4H), 7.36 (m, 1H), 7.23 (d, 1H), 5.16 (m, 1H), 4.77 (m, 1H), 4.35 (m, 1H), 3.26 (m, 1H), 2.90˜2.73 (m, 7H), 2.06 (m, 3H), 1.79 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 0.93 (m, 1H), 0.58 (m, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.79 (m, 2H), 7.55 (m, 3H), 7.45 (m, 1H), 7.27 (m, 1H), 5.17 (m, 1H), 4.77 (m, 1H), 3.35 (m, 1H), 3.26 (m, 1H), 2.92˜2.74 (m, 7H), 2.13 (br, 1H), 2.08 (m, 2H), 1.81 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 0.92 (m, 1H), 0.59 (m, 1H), 0.50 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.54˜7.41 (m, 5H), 7.26 (m, 1H), 7.27 (m, 1H), 5.16 (m, 1H), 4.77 (m, 1H), 4.35 (m, 1H), 3.26 (m, 1H), 2.94˜2.74 (m, 7H), 2.18 (br, 1H), 2.07 (m, 2H), 1.80 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 0.93 (m, 1H), 0.58 (m, 1H), 0.50 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.49 (m, 1H), 7.41 (m, 2H), 7.32 (m, 1H), 7.24 (m, 2H), 7.15 (m, 1H), 5.18 (m, 1H), 4.76 (m, 1H), 4.35 (m, 1H), 3.27 (m, 1H), 2.91˜2.73 (m, 7H), 2.13 (m, 1H), 2.08 (d, 2H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.43 (br, 1H), 0.93 (m, 1H), 0.60 (m, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.48 (d, 1H), 7.41 (d, 1H), 7.33 (m, 4H), 7.22 (m, 1H), 5.19 (m, 1H), 4.74 (m, 1H), 4.14 (m, 1H), 3.23 (m, 1H), 2.95˜2.68 (m, 7H), 2.13 (m, 3H), 1.80 (br, 1H), 1.68 (br, 1H), 1.57 (br, 1H), 1.39 (br, 1H), 0.90 (m, 1H), 0.59 (m, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.75 (d, 1H), 7.56 (m, 1H), 7.46 (m, 1H), 7.33 (m, 2H), 7.18 (s, 2H), 5.14 (m, 1H), 4.73 (m, 1H), 4.32 (m, 1H), 3.23 (m, 1H), 2.95˜2.69 (m, 7H), 2.09 (m, 3H), 1.81 (br, 1H), 169 (br, 1H), 1.56 (br, 1H), 1.38 (br, 1H), 0.89 (m, 1H), 0.59 (m, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.43˜7.31 (m, 6H), 7.20 (m, 1H), 5.15 (m, 1H), 4.75 (m, 1H), 4.33 (m, 1H), 3.27 (m, 1H), 2.95˜2.63 (m, 7H), 2.09 (m, 3H), 1.81 (br, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.39 (br, 1H), 0.93 (m, 1H), 0.57 (m, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.70 (m, 1H), 7.57˜7.46 (m, 4H), 7.28˜7.21 (m, 2H), 5.15 (m, 1H), 4.77 (m, 1H), 4.34 (m, 1H), 3.26 (m, 1H), 2.90˜2.68 (m, 7H), 2.40 (s, 3H), 2.13 (m, 3H), 1.81 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 0.94 (m, 1H), 0.58 (m, 1H), 0.48 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.56 (m, 3H), 7.42 (m, 1H), 7.22 (m, 3H), 6.74˜6.37 (t, 1H), 5.16 (m, 1H), 4.76 (m, 1H), 4.33 (m, 1H), 3.26 (m, 1H), 2.90˜2.67 (m, 7H), 2.06 (m, 3H), 1.75 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.38 (br, 1H), 0.92 (m, 1H), 0.57 (br, 1H), 0.49 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.50 (m, 3H), 7.40 (d, 1H), 7.19 (d, 1H), 7.11 (m, 2H), 5.22 (s, 2H), 5.13 (m, 1H), 4.74 (br, 1H), 4.33 (d, 1H), 3.51 (s, 3H), 3.25 (m, 1H), 2.88˜2.67 (m, 7H), 2.05 (br, 2H), 1.75 (br, 1H), 1.68 (br, 1H), 1.58 (br, 1H), 1.37 (br, 1H), 1.26 (br, 1H), 0.93 (m, 1H), 0.57 (br, 1H), 0.47 (m, 2H)
The titled compounds of Examples 186 to 226 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (6′-bromo-3′,4′-dihydro-1′H-spiro[cyclopropane-1,2′-naphthalen]-1′-yl)carbamate prepared in Preparation 5; and the corresponding substituted-boronic acids, respectively.
1H-NMR (400 MHz, CDCl3) δ 7.36 (m, 1H), 7.32 (m, 1H), 7.23 (m, 2H), 7.13 (d, 2H), 7.08 (m, 1H), 5.13 (m, 1H), 4.78 (br, 1H), 4.31 (d, 1H), 3.25 (m, 1H), 2.85˜2.76 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.37 (d, 2H), 7.33 (m, 1H), 7.25 (m, 3H), 7.12 (m, 1H), 5.13 (m, 1H), 4.77 (br, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.85˜2.76 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.68 (d, 2H), 7.40 (d, 2H), 7.25 (m, 2H), 7.12 (m, 1H), 5.13 (m, 1H), 4.77 (br, 1H), 4.36 (d, 1H), 3.25 (m, 1H), 2.85˜2.76 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.58 (m, 1H), 7.35 (d, 2H), 7.29˜7.25 (m, 3H), 7.12 (m, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.36 (d, 1H), 3.25 (m, 1H), 2.85˜2.76 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.39 (m, 3H), 7.15 (m, 1H), 7.09˜7.01 (m, 3H), 5.14 (m, 1H), 4.78 (br, 1H), 4.35 (d, 1H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.56 (m, 1H), 0.42 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.38˜7.26 (m, 5H), 7.19 (m, 1H), 7.12 (m, 1H), 5.14 (m, 1H), 4.78 (br, 1H), 4.36 (d, 1H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.59 (m, 1H), 0.46 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.62 (m, 1H), 7.56 (m, 2H), 7.39 (m, 1H), 7.29 (m, 2H), 7.13 (m, 1H), 5.14 (m, 1H), 4.78 (br, 1H), 4.36 (d, 1H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.60 (br, 1H), 1.35 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.59 (m, 1H), 0.48 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.50˜7.26 (m, 3H), 7.25˜7.13 (m, 4H), 5.14 (m, 1H), 4.78 (br, 1H), 4.35 (d, 1H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.60 (br, 1H), 1.35 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.59 (m, 1H), 0.47 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.32˜7.25 (m, 2H), 7.22 (d, 2H), 7.15 (m, 1H), 6.98 (d, 2H), 5.12 (m, 1H), 4.76 (br, 1H), 4.37 (d, 1H), 4.18 (d, 2H), 3.79 (d, 2H), 3.48 (s, 3H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.10 (br, 1H), 0.89 (m, 1H), 0.56 (m, 1H), 0.42 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.35˜7.25 (m, 3H), 7.15 (m, 1H), 6.93 (d, 1H), 6.87 (s, 2H), 5.14 (m, 1H), 4.76 (br, 1H), 4.35 (d, 1H), 4.15 (d, 2H), 3.78 (d, 2H), 3.47 (s, 3H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.05 (br, 1H), 1.94 (br, 1H), 1.80 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.38 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.35˜7.25 (m, 3H), 7.15 (m, 1H), 7.05 (m, 1H), 7.03 (m, 1H), 6.97 (d, 1H), 5.15 (m, 1H), 4.76 (br, 1H), 4.33 (m, 1H), 4.10 (m, 2H), 3.61 (m, 2H), 3.30˜3.24 (m, 3H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.05 (br, 1H), 1.94 (br, 1H), 1.80 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.38 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.32˜7.25 (m, 2H), 7.22 (d, 2H), 7.14 (m, 1H), 7.08 (d, 2H), 5.22 (s, 2H), 5.13 (m, 1H), 4.77 (br, 1H), 4.37 (d, 1H), 3.53 (s, 3H), 3.25 (m, 1H), 2.85˜2.67 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.10 (br, 1H), 0.89 (m, 1H), 0.56 (m, 1H), 0.42 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.35˜7.25 (m, 3H), 7.15 (m, 1H), 6.93 (d, 1H), 6.87 (s, 2H), 5.20 (s, 2H), 5.13 (m, 1H), 4.77 (br, 1H), 4.37 (d, 1H), 3.51 (s, 3H), 3.25 (m, 1H), 2.85˜2.67 (m, 7H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.10 (br, 1H), 0.89 (m, 1H), 0.56 (m, 1H), 0.42 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.35˜7.25 (m, 3H), 7.15 (m, 1H), 7.05 (m, 1H), 7.03 (m, 1H), 5.15 (m, 1H), 5.10˜5.07 (m, 2H), 4.77 (br, 1H), 4.36 (d, 1H), 3.32˜3.27 (m, 3H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.05 (br, 1H), 1.94 (br, 1H), 1.80 (br, 1H), 1.70 (br, 1H), 1.59 (br, 1H), 1.38 (br, 1H), 1.14 (br, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.38 (m, 1H), 7.26 (m, 1H), 7.14 (m, 1H), 7.10 (m, 1H), 7.04 (m, 1H), 6.88 (d, 1H), 5.20˜5.10 (m, 1H), 4.75 (m, 1H), 4.33 (t, 1H), 3.85 (s, 3H), 3.25 (m, 1H), 2.85˜2.73 (m, 5H), 2.46 (m, 2H), 2.05 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.10 (br, 1H), 0.88 (m, 1H), 0.56 (m, 1H), 0.42 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.39 (d, 2H), 7.26 (m, 1H), 7.13 (m, 1H), 6.84 (m, 2H), 5.14 (m, 1H), 4.75 (m, 1H), 4.35 (d, 1H), 3.91 (s, 3H), 3.25 (m, 1H), 2.86˜2.63 (m, 7H), 2.00 (m, 1H), 1.95 (br, 1H), 1.75 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.10 (br, 1H), 0.90 (m, 1H), 0.58 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.35 (m, 1H), 7.26 (m, 1H), 7.14 (m, 1H), 7.06 (m, 1H), 7.00 (m, 2H), 5.15 (m, 1H), 4.75 (m, 1H), 4.36 (d, 1H), 3.94 (s, 3H), 3.25 (m, 1H), 2.84˜2.65 (m, 7H), 2.06 (br, 1H), 1.95 (br, 1H), 1.82 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.35 (br, 1H), 1.10 (br, 1H), 0.89 (m, 1H), 0.56 (m, 1H), 0.42 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.35 (m, 2H), 7.27 (m, 1H), 7.17 (m, 1H), 7.15 (m, 3H), 5.15 (m, 1H), 4.77 (br, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.87˜2.71 (m, 7H), 2.67 (m, 2H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.26 (t, 3H), 1.10 (m, 1H), 0.90 (m, 1H), 0.59 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.40˜7.33 (m, 4H), 7.27 (m, 1H), 7.18 (m, 1H), 7.12 (d, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.38 (d, 1H), 3.25 (m, 1H), 2.87˜2.66 (m, 7H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.37 (s, 9H), 1.10 (m, 1H), 0.90 (m, 1H), 0.59 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.36 (m, 2H), 7.27 (m, 2H), 7.17 (m, 2H), 7.13 (d, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.94 (m, 1H), 2.87˜2.71 (m, 7H), 2.67 (m, 2H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.28 (m, 6H), 1.10 (m, 1H), 0.90 (m, 1H), 0.59 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.51 (m, 2H), 7.43 (m, 2H), 7.38 (m, 1H), 7.27 (m, 1H), 7.14 (m, 1H), 6.84˜6.55 (t, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.86˜2.60 (m, 7H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.10 (m, 1H), 0.90 (m, 1H), 0.59 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.39˜7.18 (m, 4H), 6.74 (d, 1H), 6.66 (s, 2H), 5.15 (m, 1H), 4.77 (br, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.97 (s, 6H), 2.86˜2.60 (m, 7H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.10 (m, 1H), 0.88 (m, 1H), 0.59 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.35˜7.15 (m, 3H), 7.15 (m, 1H), 6.86 (m, 3H), 5.15 (m, 1H), 4.77 (br, 1H), 4.57 (m, 1H), 4.35 (d, 1H), 3.25 (m, 1H), 2.85˜2.68 (m, 7H), 2.08 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 1.35 (d, 6H), 1.15 (m, 1H), 0.88 (m, 1H), 0.59 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.35 (m, 1H), 7.24 (m, 1H), 7.11 (m, 2H), 6.96 (d, 1H), 6.75 (d, 1H), 5.16 (m, 1H), 4.77 (br, 1H), 4.34 (m, 1H), 3.92 (s, 3H), 3.52 (s, 3H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.08 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 1.15 (m, 1H), 0.87 (m, 1H), 0.56 (m, 1H), 0.43 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.31 (m, 1H), 7.24 (m, 1H), 7.11 (m, 1H), 7.09 (m, 1H), 6.56 (d, 2H), 5.16 (m, 1H), 4.76 (br, 1H), 4.34 (d, 1H), 3.86 (s, 3H), 3.75 (s, 3H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.08 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 1.15 (m, 1H), 0.89 (m, 1H), 0.56 (m, 1H), 0.43 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.24 (m, 1H), 7.11 (m, 1H), 6.88 (m, 2H), 6.71 (m, 1H), 5.16 (m, 1H), 4.76 (br, 1H), 4.35 (d, 1H), 3.79 (s, 3H), 3.71 (d, 3H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.08 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 1.15 (m, 1H), 0.88 (m, 1H), 0.56 (m, 1H), 0.42 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.32 (m, 2H), 7.24 (m, 1H), 7.06 (d, 1H), 6.65 (d, 2H), 5.16 (m, 1H), 4.76 (br, 1H), 4.35 (d, 1H), 3.73 (d, 6H), 3.25 (m, 1H), 2.85˜2.74 (m, 7H), 2.08 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.58 (br, 1H), 1.39 (br, 1H), 1.15 (m, 1H), 0.89 (m, 1H), 0.56 (m, 1H), 0.40 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.33 (m, 1H), 7.24 (m, 1H), 7.18 (m, 1H), 6.92 (d, 1H), 6.85 (m, 2H), 5.14 (m, 1H), 4.77 (br, 1H), 4.35 (d, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.25 (m, 1H), 2.85˜2.67 (m, 7H), 2.08 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.69 (br, 1H), 1.58 (br, 1H), 1.39 (br, 1H), 1.15 (m, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.46 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.24 (m, 1H), 7.17 (m, 1H), 6.47 (s, 1H), 6.44 (d, 2H), 5.16 (m, 1H), 4.76 (br, 1H), 4.35 (d, 1H), 3.82 (s, 6H), 3.25 (m, 1H), 2.85˜2.67 (m, 7H), 2.08 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.69 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 1.15 (m, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.32 (m, 1H), 7.22 (m, 3H), 7.14 (m, 1H), 6.96 (m, 2H), 5.15 (m, 1H), 4.77 (br, 1H), 4.34 (d, 1H), 3.86 (s, 3H), 3.25 (m, 1H), 2.87˜2.71 (m, 7H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.10 (m, 1H), 0.90 (m, 1H), 0.59 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (t, 2H), 7.24 (m, 1H), 7.17 (m, 1H), 6.88 (m, 2H), 6.84 (s, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.34 (d, 1H), 3.86 (s, 3H), 3.25 (m, 1H), 2.87˜2.71 (m, 7H), 2.10 (br, 1H), 1.97 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.10 (m, 1H), 0.89 (m, 1H), 0.59 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.31 (m, 1H), 7.25 (m, 3H), 7.14 (m, 1H), 6.94 (d, 2H), 5.15 (m, 1H), 4.77 (br, 1H), 4.34 (d, 1H), 4.07 (m, 2H), 3.25 (m, 1H), 2.87˜2.71 (m, 7H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.47 (t, 3H), 1.40 (br, 1H), 1.10 (m, 1H), 0.90 (m, 1H), 0.59 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.33 (m, 2H), 7.24 (m, 1H), 7.15 (m, 1H), 6.89 (m, 2H), 6.83 (s, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.35 (d, 1H), 4.05 (m, 2H), 3.25 (m, 1H), 2.87˜2.71 (m, 7H), 2.10 (br, 1H), 1.98 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.45 (t, 3H), 1.40 (br, 1H), 1.10 (m, 1H), 0.89 (m, 1H), 0.59 (m, 1H), 0.45 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.32 (m, 1H), 7.24 (m, 1H), 7.21 (d, 2H), 7.13 (m, 1H), 6.93 (d, 2H), 5.15 (m, 1H), 4.77 (br, 1H), 4.57 (m, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.87˜2.71 (m, 7H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.38 (d, 6H), 1.15 (m, 1H), 0.89 (m, 1H), 0.58 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.33 (m, 1H), 7.23 (m, 3H), 7.15 (m, 1H), 6.95 (d, 2H), 5.15 (m, 1H), 4.77 (br, 1H), 4.57 (m, 1H), 4.34 (d, 1H), 3.95 (m, 2H), 3.25 (m, 1H), 2.87˜2.71 (m, 7H), 2.10 (br, 1H), 1.92 (br, 1H), 1.85 (m, 2H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.38 (d, 6H), 1.15 (m, 1H), 1.06 (t, 3H), 0.88 (m, 1H), 0.58 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.26 (m, 5H), 7.14 (m, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.57 (m, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.87˜2.71 (m, 7H), 2.67 (m, 2H), 2.10 (br, 1H), 1.92 (br, 1H), 1.85 (m, 2H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.26 (t, 3H), 1.15 (m, 1H), 1.06 (t, 3H), 0.88 (m, 1H), 0.58 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.26 (m, 5H), 7.14 (m, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.57 (m, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.87˜2.71 (m, 7H), 2.62 (m, 2H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.70 (m, 2H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.26 (t, 3H), 1.15 (m, 1H), 1.01 (t, 3H), 0.88 (m, 1H), 0.58 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.26 (m, 5H), 7.14 (m, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.57 (m, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.96 (m, 1H), 2.87˜2.68 (m, 7H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.28 (d, 6H), 1.15 (m, 1H), 0.88 (m, 1H), 0.58 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.27 (m, 1H), 7.15 (m, 5H), 5.15 (m, 1H), 4.77 (br, 1H), 4.57 (m, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.87˜2.68 (m, 7H), 2.52 (d, 2H), 2.10 (br, 1H), 1.92 (m, 2H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.15 (m, 1H), 0.92 (d, 6H), 0.88 (m, 1H), 0.58 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.44 (d, 2H), 7.34 (m, 1H), 7.23 (m, 3H), 7.15 (m, 1H), 5.15 (m, 1H), 4.77 (br, 1H), 4.57 (m, 1H), 4.34 (d, 1H), 3.25 (m, 1H), 2.87˜2.68 (m, 7H), 2.10 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (m, 1H), 1.40 (br, 1H), 1.35 (s, 9H), 1.15 (m, 1H), 0.92 (d, 6H), 0.88 (m, 1H), 0.58 (m, 1H), 0.44 (m, 2H)
1H-NMR (400 MHz, CDCl3) δ 7.34 (m, 1H), 7.27 (m, 1H), 7.19 (m, 2H), 7.10 (m, 3H), 5.15 (m, 1H), 4.77 (br, 1H), 4.36 (d, 1H), 3.25 (m, 1H), 2.85˜2.68 (m, 7H), 2.08 (br, 1H), 1.92 (br, 1H), 1.80 (br, 1H), 1.68 (br, 1H), 1.59 (br, 1H), 1.39 (br, 1H), 1.35 (d, 6H), 1.15 (m, 1H), 1.00 (m, 2H), 0.88 (m, 1H), 0.75 (m, 2H), 0.59 (m, 1H), 0.44 (m, 2H)
The titled compounds of Examples 227 to 232 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (6-bromo-7-fluoro-2,2-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate prepared in Preparation 7; and the corresponding substituted-boronic acids, respectively.
1H-NMR (400 MHz, CDCl3) δ 7.27 (m, 2H), 7.10 (d, 1H), 7.02 (m, 2H), 4.92 (m, 1H), 4.80 (m, 1H), 4.61 (d, 1H), 3.92 (s, 3H), 3.27 (m, 1H), 2.92˜2.66 (m, 7H), 2.08 (br, 1H), 1.95 (br, 1H), 1.82 (m, 2H), 1.68 (br, 1H), 1.60 (br, 1H), 1.42 (br, 1H), 1.05 (m, 3H), 0.90 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.17 (s, 2H), 7.12 (d, 1H), 7.04 (m, 1H), 4.88 (m, 1H), 4.81 (m, 1H), 4.63 (d, 1H), 3.77 (m, 2H), 3.27 (m, 1H), 2.95˜2.68 (m, 7H), 2.35 (s, 6H), 2.12 (br, 1H), 1.93 (m, 1H), 1.85 (m, 2H), 1.71 (m, 3H), 1.59 (br, 1H), 1.43 (br, 1H), 1.08 (m, 6H), 0.95 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.45 (d, 2H), 7.24 (m, 2H), 7.15 (d, 1H), 7.06 (m, 1H), 4.92 (m, 1H), 4.81 (m, 1H), 4.64 (d, 1H), 3.27 (m, 1H), 2.94˜2.69 (m, 7H), 2.62 (m, 2H), 2.14 (br, 2H), 1.85 (br, 1H), 1.70 (m, 5H), 1.60 (br, 1H), 1.42 (br, 1H), 1.07 (m, 3H), 0.99 (m, 6H)
1H-NMR (400 MHz, CDCl3) δ 7.42 (d, 2H), 7.21 (d, 2H), 7.16 (d, 1H), 7.05 (m, 1H), 4.91 (m, 1H), 4.79 (m, 1H), 4.66 (d, 1H), 3.30 (m, 1H), 2.95˜2.72 (m, 7H), 2.53 (d, 2H), 2.12 (br, 2H), 1.90 (m, 1H), 1.85 (br, 1H), 1.71 (m, 3H), 1.59 (br, 1H), 1.43 (br, 1H), 1.08 (m, 3H), 0.93 (m, 9H)
1H-NMR (400 MHz, CDCl3) δ 8.14 (d, 1H), 7.18 (d, 1H), 7.09 (m, 1H), 7.00 (br, 1H), 6.82 (s, 1H), 4.91 (m, 1H), 4.79 (m, 1H), 4.64 (d, 1H), 3.28 (m, 1H), 2.95˜2.69 (m, 7H), 2.11 (br, 1H), 1.94 (br, 1H), 1.84 (br, 1H), 1.72 (m, 3H), 1.60 (br, 1H), 1.42 (br, 1H), 1.07 (m, 3H), 0.94 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.45 (d, 2H), 7.13 (d, 1H), 7.05 (m, 1H), 6.59 (d, 2H), 4.91 (m, 1H), 4.81 (m, 1H), 4.64 (m, 2H), 3.28 (m, 1H), 2.97˜2.69 (m, 7H), 2.12 (br, 1H), 1.84 (br, 1H), 1.71 (m, 3H), 1.60 (br, 1H), 1.43 (br, 1H), 1.38 (d, 6H), 1.07 (m, 3H), 0.94 (m, 3H)
The titled compounds of Examples 233 to 238 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (6-bromo-7-methoxy-2,2-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate prepared in Preparation 8; and the corresponding substituted-boronic acids, respectively.
1H-NMR (400 MHz, CDCl3) δ 7.31 (m, 1H), 7.22 (m, 1H), 6.99 (m, 2H), 6.83 (d, 1H), 4.90 (m, 1H), 4.82 (m, 1H), 4.61 (d, 1H), 3.92 (s, 3H), 3.77 (d, 3H), 3.25 (m, 1H), 2.95˜2.77 (m, 7H), 2.09 (br, 2H), 1.86 (br, 2H), 1.67 (br, 1H), 1.57 (br, 1H), 1.41 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.12 (s, 2H), 7.00 (s, 1H), 6.84 (d, 1H), 4.84 (m, 1H), 4.81 (m, 1H), 4.60 (d, 1H), 3.75 (m, 3H), 3.26 (m, 1H), 2.89˜2.76 (m, 7H), 2.31 (s, 6H), 2.08 (br, 1H), 1.85 (m, 3H), 1.68 (m, 3H), 1.56 (br, 1H), 1.40 (br, 1H), 1.10 (t, 3H), 1.05 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.42 (d, 2H), 7.21 (d, 2H), 7.03 (s, 1H), 6.84 (d, 1H), 4.83 (m, 1H), 4.81 (m, 1H), 4.63 (d, 1H), 3.75 (d, 3H), 3.27 (m, 1H), 2.90˜2.78 (m, 7H), 2.63 (m, 2H), 2.11 (br, 2H), 1.85 (br, 1H), 1.70 (m, 5H), 1.60 (br, 1H), 1.43 (br, 1H), 1.06 (m, 3H), 0.96 (m, 6H)
1H-NMR (400 MHz, CDCl3) δ 7.42 (d, 2H), 7.15 (d, 2H), 7.06 (s, 1H), 6.86 (d, 1H), 4.87 (m, 1H), 4.73 (m, 1H), 4.64 (d, 1H), 3.78 (d, 3H), 3.28 (m, 1H), 2.89˜2.79 (m, 7H), 2.51 (d, 2H), 2.12 (br, 2H), 1.90 (m, 1H), 1.82 (br, 1H), 1.68 (m, 3H), 1.56 (br, 1H), 1.42 (br, 1H), 1.06 (m, 3H), 0.99 (m, 3H), 0.95 (d, 6H)
1H-NMR (400 MHz, CDCl3) δ 8.12 (d, 1H), 7.07 (s, 1H), 7.01 (br, 1H), 6.88 (d, 1H), 6.81 (s, 1H), 4.82 (m, 1H), 4.73 (m, 1H), 4.62 (d, 1H), 3.77 (d, 3H), 3.27 (m, 1H), 2.86˜2.74 (m, 7H), 2.11 (br, 1H), 1.94 (br, 1H), 1.84 (br, 1H), 1.77 (m, 3H), 1.60 (s, 9H), 1.43 (br, 1H), 1.08 (m, 3H), 0.99 (m, 3H)
1H-NMR (400 MHz, CDCl3) δ 7.42 (d, 2H), 7.04 (s, 1H), 6.92 (d, 2H), 683 (d, 1H), 4.86 (m, 1H), 4.80 (m, 1H), 4.70 (m, 1H), 4.60 (m, 1H), 3.79 (d, 3H), 3.26 (m, 1H), 2.88˜2.76 (m, 7H), 2.12 (br, 1H), 1.86 (br, 1H), 1.68 (m, 3H), 1.58 (br, 1H), 1.42 (br, 1H), 1.36 (d, 6H), 1.05 (m, 3H), 1.00 (m, 3H)
The inhibitory activities of the compounds of the present invention against GCS were evaluated, as follows, according to the method described in the known literature (Hayashi Y et al., A sensitive and reproducible assay to measure the activity of glucosylceramide synthase and lactosylceramide synthase using HPLC and fluorescent substrates, Analytical Biochemistry 345 (2005) 181-186). Ibiglustat, known as a GCS inhibitor, was used as a control.
(1) Materials
A549 cells (ATCC, CCL-185)
NBD C6-ceramide (Thermo Fisher, N1154)
UDP-glucose (Sigma, U4625)
Potassium chloride (Sigma, P9333)
UltraPure™ 0.5 M EDTA (Invitrogen, 15575-038)
BCA protein assay kit (Thermo Fisher, 23227)
Ibiglustat (Shanghai Systeam Biochem Co., ltd, Genz-682452)
HEPES (sigma, H3375)
Protease/phosphatase inhibitor cocktail (CST, 5872s)
DMEM (GIBCO, 11995-065)
FBS (GIBCO, 16000-044)
Antibiotic-Antimycotic (100×) (GIBCO, 15240-112)
200 mM L-glutamine (GIBCO, 25030081)
PBS (GIBCO, 10010-023)
0.25% Trypsin-EDTA (GIBCO, 25200-056)
Dimethyl sulfoxide (Sigma, 34869)
2-propanol, HPLC grade (Burdick & Jackson, AH323-4)
Hexane, HPLC grade (Burdick & Jackson, AH216-4)
Chloroform (Sigma, C2432)
Methanol (Merck, 1.06009.1011)
(2) Protocol
<1> Preparation of Cell Lysates
A549 cells (ATCC, CCL-185) were cultured in a DMEM medium supplemented with 10% fetal bovine serum (FBS), 1× antibiotic-antimycotic, and 1×L-glutamine, in an incubator at 37° C. and 5% CO2. After the cells attached to the culture dish were washed with phosphate buffered saline (PBS), the cells were scraped off with a cell scraper and then centrifuged (4000 rpm, 3 min, 4° C.) to collect the cells in a 50 ml tube. The cell pellets were suspended in a lysis buffer (50 mM HEPES, pH 7.3, containing 1× the protease/phosphatase inhibitor cocktail), lysed by sonication, and then the lysate was centrifuged (13000 rpm, 10 min, 4° C.). The obtained supernatant was used for the quantitative analysis of proteins. The amount of proteins was measured using the BCA protein assay kit, using bovine serum albumin as a standard.
<2> GCS Enzyme Reaction
Enzymatic reactions were initiated by sequentially adding the following reaction materials to a 96 deep-well plate. Thereafter, the enzymatic reactions were performed at 37°° C. for 90 minutes.
<3> Lipid Extraction
The enzymatic reactions were stopped by adding 100 μl of chloroform/methanol (2:1, v/v). After vortexing for 15 seconds, each mixture was centrifuged (4000 rpm, 10 min, 18° C.). The lower layer (50 μl) was transferred to a new 96 deep-well plate and dried with a reduced concentrator.
<4> HPLC Analysis
Lipids were dissolved in 100 μl of isopropyl alcohol/n-hexane/H2O (55:44:1, v/v/v) and then transferred to a glass vial for HPLC (Agilent, 8004-HP-H/i3u). The sample (100 μl) was automatically loaded onto a normal-phase column (Intersil SIL 150A-5, 4.6×250 mm, GL Sciences, Japan) and then eluted at a flow rate of 2.0 ml/min with isopropyl alcohol/n-hexane/H2O (55:44:1, v/v/v). The fluorescence thereof was measured with a fluorescence detector (Agilent, 1260 FLD Spectra), using 470 nm and 530 nm as excitation and emission wavelengths, respectively.
<5> Data Analysis
Data analysis was performed by the following equations.
% Area (Sample)=Area (GlcCer)/[Area (Cer)+Area (GlcCer)]×100
% GCS activity=[Area(Sample)−Area(ibiglustat)]/[Area(DMSO)−Area(ibiglustat)]×100
The obtained % GCS activity data was analyzed with the software GraphPad Prism (Ver 5.01) to calculate the IC50 values. The results are shown in Tables 1 and 2 below.
From the results of Tables 1 and 2, it can be seen that the compounds of the present invention exhibit excellent inhibitory activity against GCS.
GM1, which is the final product of sphingolipid metabolism, is expressed on the cell membrane and thus the detection thereof is easy. In addition, the amount of GM1 represents the conversion of ceramide to glucosylceramide. Therefore, the inhibitory activities of the compounds of the present invention against GM1 production were evaluated, as follows, according to the method described in the known literature (Dijkhuis et al., Gangliosides do not affect ABC transporter function in human neuroblastoma cells. The Journal of Lipid Research 47 (2006). 1187-1195). Ibiglustat, known as a GCS inhibitor, was used as a control.
(1) Materials
Jurkat cells, Clone E6-1 (ATCC, TIB-152)
Cholera toxin subunit B (CTB), FITC (Sigma, C1655)
Ibiglustat (Shanghai Systeam Biochem Co., ltd, Genz-682452)
DMSO (Sigma, D2650)
Fixation buffer (BD, 554655)
RPMI 1640 (Gibco, A1049101)
FBS (Gibco, 16000-044)
Antibiotic-Antimycotic (100×) (Gibco, 15240-122)
FACS Sheath Fluid (BD, 342003)
Jurkat cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1× Antibiotic-Antimycotic. A washing solution was prepared by adding 10 ml of FBS to 490 ml of FACS Sheath Fluid. The CTB-FITC solution was prepared by diluting the CTB-FITC stock solution (10 mg/ml) with the washing solution to a final concentration of 2 μg/ml.
(2) Protocol
A cell suspension (1×105 cells/ml) was prepared with the culture medium (RPMI 1640 medium supplemented with 10% FBS and 1× Antibiotic-Antimycotic). The cell suspension (200 μl) was added to each well of a 96-well plate (20,000 cells/well) and then the compounds were treated thereto in a final concentration of 0.05 to 3000 nM (3 fold, 11 points) per well. Each mixture was incubated in a CO2 incubator at 37° C. for 72 hours. After centrifuging at 1500 rpm for 3 minutes to remove the medium, the cells were resuspended in 200 μl of the washing solution per well. After centrifuging at 1500 rpm for 3 minutes to remove the washing solution, the cells were resuspended in 200 μl of the 2 ug/ml CTB-FITC solution. The obtained suspension was incubated at 4° C. for 60 minutes, while not being exposed to light. After centrifuging at 1500 rpm for 3 minutes to remove the CTB-FITC solution, the cells were washed with 200 μl of the washing solution. The washing process was additionally repeated twice. The washed plate was centrifuged at 1500 rpm for 3 minutes to remove the washing solution and then the cells were completely resuspended in 200 μl of the fixation buffer. IC50 was determined from the values obtained by quantifying FITC fluorescences with Guava™ easyCyte 5HT (Merck Milipore, 0500-4005).
Data analysis was performed by the following equations.
% MFI (median fluorescence intensity)=(fluorescence value of drug-treated group/fluorescence value of DMSO-treated group)×100
% Cells=(cell concentration in the well/cell concentration in the DMSO-treated group)×100
% MFI and % cell data were analyzed with the software GraphPad Prism (Ver 5.01) to calculate IC50 values. The results are shown in Tables 3 and 4 below.
From the results of Tables 3 and 4, it can be seen that the compounds of the present invention exhibit excellent inhibitory activity against GM1 production.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2019-0146684 | Nov 2019 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2020/015867 | 11/12/2020 | WO |
